Synthesis and NMDA receptor affinity of dexoxadrol analogues with modifications in position 4 of the piperidine ring

Ashutosh Banerjee; Roland Fröhlich; Dirk Schepmann; Bernhard Wünsch

doi:10.1039/C0MD00017E

View PDF VersionPrevious ArticleNext Article

DOI: 10.1039/C0MD00017E (Concise Article) Med. Chem. Commun., 2010, 1, 87-102

Show CompoundsShow Chemical TermsShow Biomedical Terms

Synthesis and NMDA receptor affinity of dexoxadrol analogues with modifications in position 4 of the piperidine ring†

Ashutosh Banerjee ^a, Roland Fröhlich ^b, Dirk Schepmann ^a and Bernhard Wünsch *^a
^aInstitut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhems-Universität Münster, Hittorfstraße 58-62, D-48149, Münster, Germany. E-mail: wuensch@uni-muenster.de; Fax: +49-251-8332144; Tel: +49-251-8333311
^bOrganisch-chemisches Institut der Westfälischen Wilhems-Universität Münster, Corrensstraße 40, D-48149, Münster, Germany

Received 22nd February 2010 , Accepted 25th March 2010

First published on 28th April 2010

Abstract

A series of dexoxadrol (3) analogues with various substituents at position 4 of the piperidine ring has been synthesized and pharmacologically evaluated. Key steps in the synthesis are a hetero-Diels–Alder reaction of the dioxolane-derived imine 10 with Danishefsky's diene 11 and replacement of the p-methoxybenzyl protective group by a Cbz group. All possible diastereomers were synthesized, respectively. It was shown that like-configuration of the ring junction (position 2 of the piperidine ring and position 4 of the dioxolane ring) and axial orientation of the C-4 substituent are crucial for high NMDA receptor affinity. 2-(2,2-Diphenyl-1,3-dioxolan-4-yl)piperidine with a hydroxy moiety at position 4 (17d, WMS-2508, K_i = 44 nM) represents the most potent NMDA antagonist with high selectivity against σ₁ and σ₂ receptors, and the polyamine binding site of the NMDA receptor. The high sensitivity of the receptor ligand interaction became evident since methyl ethers with unlike-configuration of the ring junction (19a, 19b) prefer the σ₁ receptor with high selectivity.

Introduction

(S)-Glutamate, which is the main excitatory neurotransmitter in the central nervous system (CNS), and other excitatory amino acids (EAAs) operate through two different classes of glutamate receptors. The first class are ionotropic receptors, which consists of NMDA (N-methyl-D-aspartate), AMPA (2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionate) and kainate receptors, and the second class are metabotropic receptors with the mGluR1–mGluR8 subtypes.¹ The NMDA receptor subtype, which is selectively activated by N-methyl-D-aspartate, represents the target system of the following report.

The physiological activation of the NMDA receptor is important for the development of neurons and for processes like memory and learning. However, an overactivation of the NMDA receptor leads to an increased influx of Ca²⁺-ions into neurons resulting in damage of the neuronal cells (excitotoxicity). Therefore, compounds blocking the excessive influx of Ca²⁺-ions through the NMDA receptor associated ion channel into neurons are of major interest as neuroprotective agents, which may be used for the therapy of cerebral ischemia, stroke, epilepsy and trauma (brain injury). Moreover, permanent increased activation of NMDA receptors has been discussed to be involved in the development of chronic neurodegenerative disorders like Parkinson`s disease, Alzheimer`s disease and alcohol dependency. Altogether the NMDA receptor represents an interesting target for the development of novel drugs for the therapy of neurological disorders.²

The opening of the NMDA receptor-associated cation channel is controlled by various ligands interacting with different binding sites at the receptor protein. The receptor comprises binding sites for (S)-glutamate, glycine, polyamines, Zn²⁺, Mg²⁺, H⁺ and phencyclidine (PCP, 1, Fig. 1).³


	Fig. 1 Structures of some important NMDA receptor antagonists: phencyclidine (PCP, 1); amantadine (2a); memantine (2b); dexoxadrol (3); 4-oxodexoxadrol (4).

Our interest has been focused on the PCP binding site, which is located within the cation channel. Compounds interacting with the PCP binding site work as non-competitive NMDA receptor antagonists by blocking the cation channel and inhibiting the passage of cations, in particular the influx of Ca²⁺-ions. Up to now, memantine (2b, Fig. 1) is the only NMDA receptor antagonist with moderate NMDA receptor affinity (K_i = 1.2 μM),⁴ which is used for the treatment of severe Alzheimer's Disease.⁴ The particular advantage of memantine is the fast off rate kinetic preventing the drug from accumulating in the ion channel. Therefore, memantine leaves rapidly inactivated ion channels and is not present when the next normal impulse arrives. The physiological neurotransmission is not disturbed by memantine resulting in minimal adverse effects. In contrast, pathologically tonically activated NMDA receptors are blocked by memantine.⁴ Parkinson's Disease can be treated with the desmethyl derivative amantadine (2a).

In contrast to memantine (2b), the piperidine derivative dexoxadrol (3) binds with high affinity (K_i = 11.4 nM) at the phencyclidine binding site within the NMDA receptor associated cation channel. Dexoxadrol was synthesized by Hardie et al. in the 1960s and revealed local anesthetic, spasmolytic, and central nervous system activity.⁵ Later, phencyclidine-like dissociative anesthetic activities were found.⁶ Unfortunately, clinical trials of dexoxadrol had to be stopped because of the psychotomimetic side effects. Since the severe side effects of dexoxadrol are attributed to its high NMDA receptor affinity and unfavorable kinetic properties, novel analogues with moderate affinities between those of dexoxadrol and memantine should display the desired pharmacological activity with an improved side effect profile.

Several derivatives of dexoxadrol have been synthesized in order to get more insight into the structure–affinity relationships within this compound class. In particular, the substituents and the size and the heteroatoms of the oxygen heterocycle have been modified.⁷ In addition to various N-substituents, the piperidine ring has been exchanged for simple primary, secondary and tertiary amines.^8,9

In order to broaden the structure–affinity relationships of this class of NMDA antagonist, we became interested in the influence of substituents in the piperidine moiety on the NMDA receptor affinity. For this purpose, a novel strategy for the synthesis of oxo-dexoxadrol analogues and homologues has been elaborated involving a hetero-Diels–Alder reaction.^10,11 The resulting racemic oxo-dexoxadrol 4 with the same relative configuration as dexoxadrol had a NMDA receptor affinity of 470 nM.¹⁰ This promising affinity stimulated the synthesis of further dexoxadrol derivatives modified in position 4 of the piperidine moiety.

Herein we report on the synthesis and NMDA receptor affinity of all the possible diastereomeric dexoxadrol analogues bearing OH, OCH₃, NH₂ and NHCH₃ groups at position 4 of the piperidine ring. Since the first experiments with alcohols were very promising, primary amines representing bioisosteres¹² of the alcohols, methyl ethers, which cannot act as H-bond donors and methylamines with the same size as methyl ethers but having H-bond donor and H-bond acceptor properties were included into the study.

Chemistry

The synthesis was started with the acetalization of benzophenone (6) with glycerol (5) to yield the dioxolane 7.^10,11 Swern oxidation¹³ of the primary alcohol 7 afforded the aldehyde 8,¹⁰ which was condensed with p-methoxybenzylamine (PMB-NH₂, 9) to give the imine 10. In contrast to the reported synthesis with benzylamine,^10,11 in this project the p-methoxybenzyl protective group was selected, because the chromatographic purification and separation of the products were easier. Without isolation the imine 10 was reacted with Danishefsky's diene 11^14,15 in an Yb(OTf)₃-catalyzed hetero-Diels–Alder reaction¹⁶ to afford the 1,2-disubstituted dihydropyridones 12a and 12c as a mixture of unlike- and like-configured diastereomers (unlike-12a [thin space (1/6-em)]

like12c = 43 [thin space (1/6-em)]

57). Selective reduction of the double bond of 12a/12c with LiBEt₃H in the presence of BF₃·OEt₂ yielded the piperidin-4-ones 13a (unlike configuration) and 13c (like configuration) in the ratio 41 [thin space (1/6-em)]

59, which were separated by flash chromatography (Scheme 1).


	Scheme 1 Synthesis of PMB-protected 4-oxo-dexoxadrol derivatives (only one enantiomer is shown, all compounds are racemic). Reagents and conditions: (a) TosOH·H₂O, toluene, reflux, 6 h, 73%. (b) oxalyl chloride, DMSO, CH₂Cl₂, −78 °C, 30 min, then NEt₃, rt, 72%. (c) 9, trimethyl orthoformate, rt, 16 h. (d) Yb(OTf)₃, 11, THF, 0 °C, 4 h, then 25 °C, 16 h, 75% from 8. (e) BF₃.OEt₂, THF, −78 °C, 30 min, then LiBEt₃H, −78 °C, 2 h, 37% (13a), 54% (13c).

Reduction of 13a with NaBH₄ resulted in the formation of a mixture (87 [thin space (1/6-em)] :13) of diastereomeric alcohols, which could not be separated. The same problem was faced after NaBH₄ reduction of the like-configured diastereomer 13c (diastereomeric ratio = 83:17). In order to improve the diastereoselectivity during the ketone reduction various reducing agents including L-Selectride (LiB(sec-Bu)₃H), K-Selectride (KB(sec-Bu)₃H), and LiBH₄ were investigated, but the diastereoselectivity did not exceed 88 [thin space (1/6-em)] :12 (Table 1).

Table 1 Ratio of diastereomeric alcohols after reduction of the ketones 13a and 13c with different reducing agents

Reducing agent	Diastereoselectivity after reduction of 13a	Diastereoselectivity after reduction of 13c
NaBH₄	87:13	83:17
LiBH₄	88:12	87:13
K-selectride	55:45	54:46
L-selectride	50:50	51:49

Since the separation of the diastereomeric alcohols failed due to considerable tailing of the basic amines, the p-methoxybenzyl (PMB) protective group of 13a and 13c was replaced by the benzyloxycarbonyl (Cbz) protective group. After hydrogenolytic removal (H₂, Pd/C) of the PMB group, the deprotected piperidines 14a and 14c were acylated with benzyl chloroformate (Cbz-Cl) in the presence of triethylamine to yield the Cbz-protected piperidines 15a and 15c, respectively. The ketones 15a and 15c were reduced unselectively with NaBH₄ to afford 1 [thin space (1/6-em)] :1 mixtures of diastereomeric alcohols 16a/16b and 16c/16d, respectively, which were separated by fc. Finally, the Cbz group of 16a–d was removed upon hydrogenolysis with H₂, Pd/C to yield the piperidines 17a–d (Scheme 2).


	Scheme 2 Synthesis of 4-hydroxy dexoxadrol derivatives (only one enantiomer is shown, all compounds are racemic). Reagents and conditions: (a) H₂, Pd/C 10%, MeOH, 16 h, rt. (b) PhCH₂OCOCl, NEt₃, THF, 1 h, rt, 83% (15a from 13a), 86% (15c from 13c). (c) NaBH₄, MeOH, 1 h, 0 °C, 43% (16a), 45% (16b), 43% (16c), 47% (16d). (d) H₂, Pd/C 10%, MeOH, 4 h, rt, 80% (17a), 75% (17b), 88% (17c), 89% (17d).

The relative configuration of the three centers of chirality was assigned by an X-ray crystal structure analysis. For this purpose, a sample of 17d was recrystallized from an n-hexane–CH₂Cl₂ mixture to get crystals, which were suitable for an X-ray structure analysis (Fig. 2). The structure of the racemic compound 17d proved the like-configuration (RS/RS) of the two centers of chirality at position 4 of the 1,3-dioxolane ring and position 2 of the piperidine ring (ring junction). The configuration of the third center of chirality at position 4 of the piperidine ring is correlating with the configuration of the other two centers of chirality. However, the piperidine 17d consists of the two enantiomers (R,R,R)-17d and (S,S,S)-17d. The relative configurations of the diastereomers of 17d as well as all precursors 12–16 were deduced from this X-ray crystal structure analysis and comparison of the corresponding NMR data.


	Fig. 2 X-Ray crystal structure of 17d (racemic).

In order to obtain the corresponding methoxy derivatives 19a–d the alcohols 16a–d were deprotonated with NaH and subsequently methylated with methyl iodide in DMF. Treatment of the methyl ethers 18a–d with H₂ and Pd/C led to cleavage of the Cbz-protective group and the four diastereomeric methoxy derivatives 19a–d were isolated in 77–90% yields (Scheme 3).


	Scheme 3 Synthesis of 4-methoxy dexoxadrol derivatives (only one enantiomer is shown, all compounds are racemic). Reagents and conditions: (a) NaH, MeI, DMF, 4 h, rt, 85% (18a), 80% (18b), 93% (18c), 91% (18d). (b) H₂, Pd/C 10%, MeOH, 4 h, rt, 78% (19a), 90% (19b), 81% (19c), 77% (19d).

During the analysis of the ¹H NMR spectra an interesting flip of the piperidine ring was observed. Whereas the piperidine ring of derivatives with a proton (e.g.14, 17, 19) or a PMB group (e.g.13) attached to the N-atom adopts the ₁C⁴ conformation, the corresponding Cbz derivatives (e.g.15, 16, 18) exist in the ¹C₄-conformation. Due to allylic strain^17,18 the N-acyl-residue of 15, 16 and 18 forces the substituent in position 2 to adopt an axial orientation, which is only possible after changing the piperidine ring conformation. This piperidine ring flip is of particular importance for the interpretation of the ¹H NMR data and the correct assignment of the relative configuration of all products. For example, the tt (J = 11.2/4.5 Hz) at 3.52 ppm in the ¹H NMR spectrum of the Cbz-derivative 18d clearly indicates an axial orientation of 4-H, and the quintet (J = 2.9 Hz) at 3.60 ppm in the ¹H NMR spectrum of the secondary amine 19d proves the equatorial position of 4-H.

For the synthesis of amino substituted dexoxadrol derivatives reductive aminations¹⁹ of the PMB-protected ketones 13a and 13c were performed. Although the transformations were successful, the separation of the formed diastereomeric amines was not possible. Therefore, again the Cbz protected ketones 15a and 15c were used for the introduction of amino moieties.

The reductive amination of unlike-configured ketone 15a with benzylamine or methylamine in the presence of NaBH(OAc)₃¹⁹ led to the diastereomeric benzylamines 20a/20b and methylamines 22a/22b in the ratio ≈7 [thin space (1/6-em)] :3, respectively, which were separated by flash chromatography (Scheme 4). Subsequent hydrogenolytic removal of the Cbz-protective group resulted in the primary amines 21a and 21b, since the benzyl moiety of the 4-benzylamino group was also cleaved, and the methylamines 23a and 23b.


	Scheme 4 Synthesis of 4-amino dexoxadrol derivatives (only one enantiomer is shown, all compounds are racemic). Reagents and conditions: (a) PhCH₂NH₂ or MeNH₂, NaBH(OAc)₃, CH₂Cl₂, 2 h, rt, 58% (20a), 29% (20b), 92% (20c), 64% (22a), 26% (22b), 90% (22c). (b) PhCH₂NH₂ or MeNH₂, trimethyl orthoformate, 14 h, rt; then NaBH₄, MeOH, 1.5 h, 0 °C, 59% (20c), 37% (20d), 47% (22c), 36% (22d). (c) H₂, Pd/C 10%, MeOH, 4 h, rt, 89% (21a), 87% (21b), 91% (21c), 83% (21d), 89% (23a), 78% (23b), 87% (23c), 82% (23d).

In contrast to ketone 15a, a high diastereoselectivity was observed during the reductive amination of like-configured ketone 15c with benzylamine or methylamine and NaBH(OAc)₃, which yielded the diastereomeric amines 20c/20d and 22c/22d in the ratio of about 9 [thin space (1/6-em)] :1. The main diastereomers 20c and 22c were isolated by flash chromatography, and subsequently treated with H₂ and Pd/C to obtain the primary amine 21c and the methylamine 23c, respectively.

In order to get the fourth diastereomers 21d and 23d, ketone 15c was first converted into imines upon stirring with benzylamine or methylamine in trimethyl orthoformate overnight. After removal of the volatile components, methanol was added to the residue and the imines were reduced with NaBH₄ at 0 °C. This procedure yielded the diastereomeric benzylamines 20c and 20d in the ratio 61 [thin space (1/6-em)] :39 and the methylamines 22c and 22d in the ratio 57:43 after fc. After separation of the diastereomers hydrogenolytic cleavage led to the final amines 21d and 23d.

During this reaction sequence the above described flip of the piperidine ring was also observed, when the N-substituent was changed from the Cbz-group (20/22) to a proton (21/23).

Receptor binding studies

The affinities of the novel dexoxadrol analogues to the PCP binding site of the NMDA receptor were determined in competition experiments using the potent and selective radioligand [³H]-(+)-MK-801. A membrane preparation from pig brain cortex was employed as receptor material.^20,21 In addition to the affinity towards the PCP binding site the affinity of selected compounds towards the ifenprodil binding site of NR2B containing NMDA receptors was investigated. For this purpose the competitive receptor binding assay recently developed in our group was used. Briefly, in this assay tritium-labelled ifenprodil was employed as a radioligand. Membrane homogenates prepared from L(tk−) cells stably expressing recombinant human NR1a/NR2B receptors served as receptor material. The high density of NMDA receptors renders this system selective.²²

Since some potent NMDA receptor antagonists also interact with σ receptors and vice versa,^23,24 the σ₁ and σ₂ receptor affinity of the piperidines was also determined. In the σ assays, the radioligands [³H]-(+)-pentazocine (σ₁) and [³H]-(+)-ditolylguanidine (σ₂), and membrane preparations from guinea pig brains (σ₁) and rat livers (σ₂) were used. In the σ₂ assay, the σ₁ binding sites were selectively masked with an excess of non-tritiated (+)-pentazocine.^25,26,27

The Cbz-protected compounds 20 and 22 were also included into his study, because they contain a basic functional group. It should be noted that the basic amino group is at another position of the piperidine ring and the O-heterocycle in position 2 adopts an axial orientation in these compounds.

The receptor binding data are summarized in Table 2. For compounds with high NMDA affinity the competition curves with six compound concentrations were recorded three times and the resulting K_i-values with SEM are given. For compounds showing only low NMDA receptor interaction in the first screening, only the inhibition (%) at a compound concentration of 1 μM is given in Table 2. Some compounds indicated promising σ₁ and/or σ₂ affinities in the first screening. However, recording of the complete competition curves revealed only low affinity, and therefore the experiments were performed only once (n = 1).

Table 2 Affinities of the dexoxadrol analogues towards NMDA (PCP), σ₁ and σ₂ receptors ugraphic, filename = c0md00017e-u1.gif

Compound	X	R	Stereochemistry^b	K _i ± SEM/nM^a
Compound	X	R	Stereochemistry^b	NMDA (PCP) ([³H]-(+)-MK-801)	σ₁ ([³H]-(+)-pentazocine)	σ₂([³H]-di-o-tolylguanidine)
a The K_i-values were determined in three independent experiments (n = 3) unless otherwise noted. b All compounds were tested as racemic mixtures. In the column stereochemistry the relative configuration of the three centers of chirality is given. c Percent inhibition at a concentration of 1μM of the test compound.
14a ¹⁰	O	H	2S-4′R	84%	1390 ± 90	54%
14c ¹⁰	O		2S-4′S	470 ± 173	0%	36%
17a	OH		2S,4R-4′R	0%^c	318 (n = 1)	0%^c
17b			2S,4S-4′R	3%^c	259 (n = 1)	30%^c
17c			2S,4R-4′S	527 ± 106	1250 (n = 1)	2%^c
17d (WMS-2508)			2S,4S-4′S	44 ± 13	971 (n = 1)	13%^c
19a	OCH₃		2S,4R-4′R	37%^c	17 ± 4.5	18%^c
19b			2S,4S-4′R	21%^c	15 ± 1.8	23%^c
19c			2S,4R-4′S	49%^c	0%^c	5%^c
19d			2S,4S-4′S	981 ± 96	831 (n = 1)	9%^c
20a	NHCH₂Ph	Cbz	2S,4R-4′R	8%^c	12%^c	23%^c
20b			2S,4S-4′R	30%^c	20%^c	442 (n = 1)
20c			2S,4R-4′S	20%^c	0%^c	14%^c
20d			2S,4S-4′S	15%^c	179 (n = 1)	8%^c
21a	NH₂	H	2S,4R-4′R	26%^c	45%^c	15%^c
21b			2S,4S-4′R	25%^c	0%^c	13%^c
21c			2S,4R-4′S	44%^c	20%^c	26%^c
21d			2S,4S-4′S	17%^c	33%^c	17%^c
22a	NHCH₃	Cbz	2S,4R-4′R	7%^c	22%^c	28%^c
22b			2S,4S-4′R	7%^c	17%^c	18%^c
22c			2S,4R-4′S	10%^c	353 (n = 1)	42%^c
22d			2S,4S-4′S	6%^c	8%^c	35%^c
23a	NHCH₃	H	2S,4R-4′R	16%^c	40%^c	44%^c
23b			2S,4S-4′R	16%^c	972 (n = 1)	3670 (n = 1)
23c			2S,4R-4′S	40%^c	21%^c	12%^c
23d			2S,4S-4′S	30%^c	32%^c	37%^c
dexoxadrol	—			11 ± 0.3	—	—
(+)-MK-801	—			2.8 ± 1.8	—	—
(+)-pentazocine	—			—	4.2 ± 1.1	—
di-o-tolyl guanidine	—			—	89 ± 29	58 ± 18

The receptor binding data in Table 2 clearly show that the compounds 20–23 with a basic amino moiety at position 4 do not interact significantly with the PCP binding site of the NMDA receptor. Moreover, the σ₁ and σ₂ receptor affinity of the amines 20–23 was also very low. The K_i-value of the most potent basic σ₁ ligand (20d) is considerably higher than 100 nM, indicating very low σ₁ affinity.

In the alcohol (17) and methyl ether series (19) the stereochemistry plays a crucial role for the NMDA receptor affinity. In particular, the two centers of chirality at position 2 of the piperidine ring and in position 4 of the 1,3-dioxolane ring (ring junction) should be like-configured. This observation is in good accordance with literature results showing that dexoxadrol with (S,S)-configuration represents the most potent stereoisomer.⁶ Additionally, the stereocenter at position 4 of the piperidine ring should have the same configuration as the other two stereocenters. This results in an axial orientation of the functional group at position 4 of the piperidine ring. The effect of the stereochemistry on the NMDA receptor affinity becomes particularly evident for the alcohol series 17. Whereas 17a and 17b with unlike-configuration of the ring junction didn't interact considerably with the NMDA receptor, the like-configured derivatives 17c and 17d were considerably more active. The racemic piperidine 17d (WMS-2508) with an axially oriented OH-moiety provided a K_i-value of 44 nM, which is slightly increased compared with the K_i-value of the enantiomerically pure lead compound dexoxadrol (11.4 nM). Despite its 15-fold lower affinity, the potency of the diastereomer 17c (K_i = 527 nM) is still in a promising range considering the affinity of memantine (compare Introduction).

Replacement of the OH-moiety at position 4 of the piperidine derivative 17d by a methoxy group (19d) led to a drastic reduction of the NMDA receptor affinity (19d: K_i = 981 nM). We assume that the reduced affinity of the methyl ether 19d is due to the increased size of the methoxy group compared with the smaller hydroxy group.

Only negligible inhibition of radioligand binding at the ifenprodil binding site of the NMDA receptor was detected at a concentration of 1 μM for the test compounds 17c (30% inhibition), 17d (0% inhibition) and 19d (29% inhibition). The low inhibition indicates IC₅₀ values higher than 1 μM for these test compounds. Obviously, at least the most potent ligand 17c, 17d and 19d reveal high selectivity for the PCP binding site over the ifenprodil binding site of the NMDA receptor.

Concerning σ₁ receptor affinity, the stereochemistry at the ring junction is also very important. In contrast to the NMDA receptor, the σ₁ receptor prefers piperidines with unlike-configuration of the ring junction. The unlike-configured alcohols 17a and 17b show moderate σ₁ affinities and the corresponding methyl ethers 19a and 19b are very potent σ₁ ligands (K_i = 17 and 15 nM). Comparison of the σ₁ affinities of the diastereomers 17a/17b and 19a/19b clearly indicates that the configuration at position 4 of the piperidine moiety is of minor importance for the σ₁ affinity.

Conclusion

The influence of substituents in position 4 of the piperidine moiety of dexoxadrol analogues on the NMDA and σ receptor affinity has been investigated. Potent NMDA antagonists were obtained, when a hydroxy moiety was introduced into position 4. like-configuration of the ring junction (position 2 of the piperidine ring and position 4 of the 1,3-dioxolane ring) as well as axial orientation of the OH moiety are crucial for high NMDA receptor affinity. The most potent NMDA antagonist 17d was very selective against σ₁ receptors, σ₂ receptors and the ifenprodil binding site of the NMDA receptor. However, changing of the configuration of the ring junction led to potent and selective σ₁ ligands (19a, 19b). Since the prepared compounds are still racemic mixtures, the NMDA and σ₁ receptor affinities will be further increased by enantiomerically pure ligands. Having the low NMDA receptor affinity of memantine with its ideal binding kinetic at the NMDA receptor in mind the alcohol 17c and the methyl ether 19d with moderate NMDA receptor affinity could also be of interest with respect to the side effect profile.

Experimental

Chemistry general

Unless otherwise noted, moisture and oxygen sensitive reactions were conducted in dry glassware (Schlenk flask sealed with a rubber septum) under N₂ (dried with phosphorous pentoxide (Granusic^® A, Baker)). Yb(OTf)₃ (Aldrich) was stored in a desiccator over P₄O₁₀ in vacuo at rt. Danishefsky's diene 11 was stored under N₂ at −25 °C. THF was dried with sodium/benzophenone and was freshly distilled before use. Methanol was dried with magnesium and iodine, distilled, and stored over molecular sieves 4 Å. CH₂Cl₂ was dried with CaH₂ and freshly distilled before use. Thin layer chromatography (tlc): Silica gel 60 F254 plates (Merck). Flash chromatography (fc): Silica gel 60, 40–64 μm (Merck); parentheses include: Diameter of the column (cm), length of the stationary phase (cm), eluent, fraction size (mL) and retention factor R_f. Melting point: melting point apparatus SMP 3 (Stuart Scientific), uncorrected. IR: IR spectrophotometer 480Plus FT-ATR-IR (Jasco). ¹H NMR (400 MHz, 300 MHz, 600 MHz), ¹³C NMR (100 MHz) and ¹⁹F NMR (300 MHz, 600 MHz) spectra were recorded on a Unity Mercury Plus 400 (400 MHz) NMR spectrometer (Varian), Brucker AV 300 (300 MHz), and Varian Unity Plus 600 (600 MHz) operating at 23 °C. High temperature NMR was recorded in Unity Mercury Plus 400 (400 MHz) NMR spectrometer (Varian) at 100 °C. Chemical shifts δ are reported in parts per million (ppm) against the reference compound tetramethylsilane and calculated using the chemical shift of the signal of the residual non-deuterated solvent, for ¹⁹F NMR chemical shifts δ are reported in parts per million (ppm) against the reference compound CFCl₃ and calculated using the chemical shift of the signal of the solvent. High temperature ¹H NMR spectra were recorded using C₆D₅NO₂ as solvent. MS: HRMS (ESI): Finnigan MAT 4200s, Brucker Daltonics Micro Tof and Waters Micromass Quatro LCZ, peaks are given in m/z (% of basis peak). EI, electron impact, MAT GCQ (Thermo-Finnigan). HPLC: Merck Hitachi Equipment; UV detector: L-7400; autosampler: L-7200; pump: L-7100; degasser: L-7614; column: LiChrospher^® 60 RP-select B (5 μm); LiChroCART^® 250–4 mm cartridge; flow rate: 1.000 mL min⁻¹; injection volume: 5.0 μL; detection at λ = 210 nm; Method A: solvents: A: water with 0.05% (v/v) trifluoroacetic acid; B: acetonitrile with 0.05% (v/v) trifluoroacetic acid: gradient elution: (A%): 0–4 min: 90%, 4–29 min: gradient from 90%, to 0%, 29–31 min: 0%, 31–31.5 min: 0% to 90%, 31.5–40 min: 90%; Method B: solvents: A: water with 0.05% (v/v) trifluoroacetic acid; B: methanol with 0.05% (v/v) trifluoroacetic acid: gradient elution: (A%): 0–1 min: 80%, 1–22 min: gradient from 80%, to 0%, 22–30 min: 0%, 30–31.5 min: 0% to 80%, 31.5–40 min: 80%. The purity of all test compounds was greater than 95%, which was determined by one of the given HPLC methods.

General procedures

General procedure A: exchange of the PMB group for the Cbz group. The PMB-piperidone 13 was dissolved in MeOH (6 mL), Pd/C 10% was added and the suspension was stirred under H₂ atmosphere (balloon) at rt overnight. The reaction mixture was filtered through Celite^®, which was rinsed with MeOH and the filtrate was evaporated to dryness. Under N₂ the crude product was dissolved in THF and Cbz-Cl (1.5 equivalents) was added followed by NEt₃ (1.5 equivalents). The reaction mixture was stirred at rt for 1 h. Then a saturated solution of NaHCO₃ and EtOAc were added. The organic layer was separated and the aqueous layer was extracted twice with EtOAc. The organic layer was dried (K₂CO₃) filtered and concentrated in vacuo. The residue was purified by fc (3 cm, 12 cm, petroleum ether–EtOAc = 7 [thin space (1/6-em)]

3, 10 mL).

General procedure B: reduction of ketones 15 to alcohols. A solution of the Cbz-protected ketone 15 in methanol (2 mL) was cooled down to 0 °C under N₂ atmosphere. Then 1 equivalent of NaBH₄ was added and the reaction mixture was stirred at 0 °C for 1 h. Water and EtOAc were added, the organic layer was separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried (K₂CO₃), filtered and concentrated in vacuo. The diastereomeric alcohols were separated by fc (2 cm, 15 cm, petroleum ether–EtOAc = 7 [thin space (1/6-em)]

3, 10 mL).

General procedure C: conversion of alcohols 16 into methyl ethers. Under N₂ the alcohol 16 was dissolved in DMF (2 mL). Then NaH (2 equivalents) was added followed by CH₃I (1 equivalent). The reaction mixture was stirred at rt for 4 h. Then ice cold water and EtOAc were added. The organic layer was separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried (K₂CO₃,) filtered and concentrated in vacuo. The residue was purified by fc (2 cm, 12 cm, petroleum ether–EtOAc = 7 [thin space (1/6-em)]

3, 20 mL).

General procedure D: conversion of ketones 15 into amines using NaBH(OAc)₃. To a solution of the Cbz-protected ketone 15 in CH₂Cl₂ (2 mL) 1.5 equivalents of benzylamine or methylamine were added followed by 1.5 equivalents of NaBH(OAc)₃. The reaction mixture was stirred at rt for 2 h. Then 1 M NaOH solution (2 mL) was added followed by CH₂Cl₂. The organic layer was separated and the aqueous layer was extracted twice with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄), filtered and concentrated in vacuo. The diastereomeric amines were separated by fc (2 cm, 15 cm, petroleum ether–EtOAc = 7 [thin space (1/6-em)]

3 for benzyl amine, EtOAc–NEtMe₂ = 9 [thin space (1/6-em)]

1 for methyl amine, 10 mL).

General procedure E: reduction of ketones 15 to amines via imines using sodium borohydride. To a solution of the Cbz-protected ketone 15 in trimethyl orthoformate (2 mL) 1.5 equivalents of benzylamine or methylamine were added and the reaction mixture was stirred at rt for 14 h. Then the solvent was evaporated in vacuo. The residue was dissolved in MeOH (2 mL) and the mixture was cooled down to 0 °C. Then 1.5 equivalents of NaBH₄ were added and the reaction mixture was stirred at 0 °C for 1.5 h. Water and EtOAc were added, the organic layer was separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried (K₂CO₃), filtered and concentrated in vacuo. The diastereomeric amines were separated by fc (2 cm, 15 cm, petroleum ether–EtOAc = 7 [thin space (1/6-em)]

3 for benzyl amine, EtOAc–NEtMe₂ = 9 [thin space (1/6-em)]

1 for methyl amine, 10 mL).

General procedure F: removal of the Cbz protective group. The Cbz-protected piperidine was dissolved in MeOH (6 mL), Pd/C (10%) was added and the suspension was stirred under H₂ atmosphere (balloon) at rt for 4 h. The reaction mixture was filtered through Celite^®, which was rinsed with MeOH and the filtrate was evaporated to dryness. The product was purified by fc (2 cm, 12 cm, EtOAc–MeOH–NEtMe₂ = 94 [thin space (1/6-em)]

1, 10 mL) for the hydroxyl and methoxy derivatives and (2 cm, 12 cm, MeOH–NEtMe₂ = 99 [thin space (1/6-em)]

1, 5 mL) for the amine derivatives.

(±)-(2RS)-1-(4-Methoxybenzyl)-2-[(4SR) and (4RS)-2,2-diphenyl-1,3-dioxolan-4-yl)]-2,3-dihydropyridin-4(1H)-one (12a and 12c). The aldehyde 8 (787.4 mg, 3.1 mmol) was dissolved in trimethyl orthoformate (5 mL), 4-methoxybenzylamine (PMB-NH₂9, 0.4 mL, 3.1 mmol) was added and the solution was stirred overnight at rt. The mixture was evaporated to dryness, the obtained yellow oil was dissolved in THF (10 mL) and the resulting solution was cooled down to 0 °C. Then a solution of Yb(OTf)₃ (384 mg, 0.62 mmol) in THF (2 mL) was added and the mixture was stirred at 0 °C for 15 min. Then, Danishefsky's diene 11 (1.08 mL, 5.67 mmol) was added and it was stirred for another 4 h at 0 °C before the reaction mixture was allowed to warm to rt overnight. A saturated solution of NaHCO₃ and EtOAc were added, the organic layer was separated, the aqueous layer was extracted twice with EtOAc, the organic layer was dried (K₂CO₃), filtered and concentrated in vacuo. The residue was purified by fc (2 cm, 12 cm, cyclohexane–EtOAc = 1 [thin space (1/6-em)]

1, 20 mL, R_f 0.20). Yellow oil, yield 1.0133 g (75%). IR (neat): ν/cm⁻¹ = 1637 (m, C [double bond, length as m-dash]

O), 1579 (s, C [double bond, length as m-dash]

C), 1071 (m, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.97 (d, J = 16.9 Hz, 0.43 H, 3^x-H), 2.48 (dd, J = 16.9/2.8 Hz, 0.57 H, 3°-H), 2.68 (dd, J = 16.9/7.9 Hz, 0.57 H, 3°-H), 2.73 (dd, J = 16.9/7.3 Hz, 0.43 H, 3^x-H), 3.45–3.49 (m, 0.43 H, 2^x-H), 3.71 (dd, J = 8.6/5.9 Hz, 0.43 H, OCH₂^x), 3.77–3.79 (m, 0.57 H, OCH₂°), 3.80 (s, 3 × 0.57 H, OCH₃°), 3.81 (s, 3 × 0.43 H, OCH₃^x), 3.99 (dd, J = 8.3/6.9 Hz, 0.57 H, OCH₂°), 4.04 (dd, J = 8.6/6.7 Hz, 0.43 H, OCH₂^x),4.05–4.09 (m, 0.57 H, OCH°), 4.29 (d, J = 14.9 Hz, 0.57 H, PhCH₂°), 4.30–4.34 (m, 0.57 H, 2°-H), 4.41 (d, J = 14.9 Hz, 0.57 H, PhCH₂°), 4.44 (d, J = 14.7 Hz, 0.43 H, PhCH₂^x), 4.65 (d, J = 14.9 Hz, 0.43 H, PhCH₂^x), 4.82 (dt, J = 9.8/6.3 Hz, 0.43 H, OCH^x), 4.94 (d, J = 7.5 Hz, 1H, 5^x-H + 5°-H), 6.85–6.89 (m, 3H, 2 × Ph + 6^x-H + 6°-H), 7.02–7.15 (m, 3H, Ph), 7.26–7.34 (m, 5H, Ph), 7.47–7.52 (m, 4H, Ph). The ratio of 12a [thin space (1/6-em)]

12c = 43 [thin space (1/6-em)]

57; ° = index for the major diastereomer 12c; ^x = index for the minor diastereomer 12a. ¹³C NMR (CDCl₃): δ (ppm) = 36.7 (C-3°), 37.3 (C-3^x), 55.2 (C-2°), 56.1 (C-2^x), 58.2 (OC°H₃, OC^xH₃), 58.7 (PhC°H₂), 59.4 (PhC^xH₂), 66.7 (OC°H₂), 66.8 (OC^xH₂), 74.1 (OC°H, OC^xH), 96.8 (C5^x), 98.5 (C5°), 109.4 (OC°O), 110.5 (OC^xO), 114.2/ 114.3/ 125.6/ 125.8/ 125.9/ 126.0/ 128.0/ 128.1/ 128.2/ 128.3/ 128.5/ 128.7/ 128.9/ 141.6/ 141.8/ 141.9 (PhC), 152.6 (C-6^x), 153.2 (C-6°), 159.4/159.5 (PhC), 188.7 (C-4^x), 189.5 (C-4°). HRMS: calcd. for C₂₈H₂₇NO₄H 442.2018, found 442.2013. HPLC (Method A): Purity 42% (12a), t_R = 22.6 min, 53% (12c), t_R = 22.0 min, together 95%.

(±)-(2RS)-1-(4-Methoxybenzyl)-2-[(4SR)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidin-4-one (13a) and (±)-(2RS)-1-(4-Methoxybenzyl)-2-[(4RS)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidin-4-one (13c). Under N₂12a/c (43 [thin space (1/6-em)]

57, 1.0133 g, 2.3 mmol) was dissolved in THF (10 mL) and the solution was cooled down to −78 °C, BF₃·OEt₂ (0.58 mL, 4.6 mmol) was added slowly and the solution was stirred for 30 min at −78 °C. Then a 1M solution of LiEt₃BH in THF (4.61 mL, 4.6 mmol) was added slowly and the reaction mixture was stirred for 2 h at −78 °C. Afterwards a saturated solution of NaHCO₃ and EtOAc were added and the reaction mixture was warmed to rt. Then EtOAc was added, the organic layer was separated, the aqueous layer was extracted twice with EtOAc, the organic layer was dried (K₂CO₃), filtered and concentrated in vacuo. The residue was purified by fc (4 cm, 20 cm, petroleum ether–EtOAc = 85 [thin space (1/6-em)]

15, 20 mL).

Compound 13a (R_f 0.16): Pale yellow oil, yield 0.3752 g (37%). IR (neat): ν/cm⁻¹ = 1714 (s, C [double bond, length as m-dash] O), 1205(s) / 1070 (s, –C–O–C–). ¹H NMR (CDCl₃): δ (ppm) = 2.21 (ddd, J = 14.7/ 5.0/1.3 Hz, 1H, 5-H), 2.26–2.33 (m, 1H, 5-H), 2.40–2.47 (m, 1H, 3-H), 2.66 (ddd, J = 14.8/5.9/0.9 Hz, 1H, 3-H), 2.78–2.84 (m, 1H, 6-H), 3.17 (ddd, J = 12.9/8.3/4.7 Hz, 1H, 6-H), 3.31 (q, J = 5.6 Hz, 1H, 2-H), 3.82 (s, 3H, OCH₃), 3.85 (d, J = 13.4 Hz, 1H, PhCH₂), 3.94 (t, J = 7.6 Hz, 1H, OCH₂), 4.05 (d, J = 13.4 Hz, 1H, CH₂Ph), 4.07 (dd, J = 7.8/7.0 Hz, 1H, OCH₂), 4.37 (q, J = 7.2 Hz, 1H, OCH), 6.87–6.89 (m, 2H, Ph), 7.25–7.37 (m, 8H, Ph), 7.48–7.55 (m, 4H, Ph). HRMS: calculated for C₂₈H₂₉NO₄H 444.2169, found 444.2164. EI (70 eV): m/z (rel. int.) = 443 (M⁺, 2), 366 (M-Ph, 2), 218 (M- diphenyldioxolanyl, 10), 121 (CH₂C₆H₄OCH₃, 100), 77 (Ph, 18). HPLC (Method A): Purity 95%, t_R = 18.6 min.

Compound 13c (R_f 0.11): Pale yellow oil, yield 0.5477 g (54%). IR (neat): ν/cm⁻¹ = 1709 (s, C [double bond, length as m-dash] O), 1450 (m, C–H), 1205 (s) / 1069 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 2.30 (dt, J = 15.1/3.8 Hz, 1H, 5-H), 2.51(ddd, J = 15.4/9.5/6.1 Hz, 1H, 5-H), 2.64 (dd, J = 14.9/5.9 Hz, 1H, 3-H), 2.71 (ddd, J = 14.8/4.0/1.2 Hz, 1H, 3-H), 2.96 (dt, J = 10.8/5.1 Hz, 1H, 6-H), 3.11–3.20 (m, 2H, 2-H + 6-H), 3.81 (s, 5H, OCH₃, CH₂Ph), 3.88 (dd, J = 8.0/7.0 Hz, 1H, OCH₂) 4.08 (dd, J = 8.1/7.1, 1H, OCH₂), 4.30 (q, J = 6.8 Hz, 1H, OCH), 6.87–6.89 (m, 2H, Ph), 7.23–7.37 (m, 8H, Ph), 7.43–7.45 (m, 2H, Ph), 7.52–7.54 (m, 2H, Ph). HRMS: calcd. for C₂₈H₂₉NO₄H 444.2169, found 444.2173. EI (70 eV): m/z (rel. int.) = 443.2 (M⁺, 2), 218 (M-diphenyldioxolanyl, 12), 121(CH₂C₆H₄OCH₃, 100), 77 (Ph, 18). HPLC (Method A): Purity 96%, t_R = 19.2 min.

(±)-Benzyl (2RS)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-oxopiperidine-1-carboxylate (15a). According to General Procedure A the piperidone 13a (0.3752 g, 0.84 mmol) was transformed into the secondary amine 14a, (crude yield 0.241 g, 88%). The crude product 14a (0.241 mg, 0.75 mmol) was dissolved in THF (3 mL) and PhCH₂OCOCl (0.16 mL, 1.12 mmol) was added followed by NEt₃ (0.16 mL, 1.12 mmol). The residue was purified by fc (R_f 0.36). Colorless oil, yield 323.4 mg (83%). IR (neat): ν/cm⁻¹ = 1695 (s, C = O/Cbz C [double bond, length as m-dash]

O), 1206 (s) /1080 (s, C–O–C). ¹H NMR (C₆D₅NO₂, 100 °C): δ (ppm) = 1.92 (dd, J = 15.7/3.4 Hz, 1H, 3-H), 2.02–2.11 (m, 1H, 5-H), 2.15 (d broad, J = 15.7 Hz, 1H, 3-H), 2.34 (ddd, J = 15.2/7.5/2.6 Hz, 1H, 5-H), 3.13 (ddt, J = 15.1/11.4/3.9 Hz, 1H, 6-H), 3.56 (ddd, J = 15.0/ 7.5/3.5 Hz, 1H, 6-H), 3.60–3.64 (m, 1H, 2-H), 3.87–3.96 (m, 2H, OCH₂Ph), 4.47–4.53 (m,1H, OCH), 4.75 (dd, J = 12.6/3.1 Hz, 1H, OCH₂), 4.82 (dd, J = 12.6/3.2 Hz, 1H, OCH₂), 6.76–7.17 (m, 15 H, Ph). HRMS: calcd. for C₂₈H₂₇NO₅Na 480.1787, found 480.1781. HPLC (Method A): Purity 98%, t_R = 22.9 min.

(±)-Benzyl (2RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-oxopiperidine-1-carboxylate (15c). According to General Procedure A the piperidone 13c (0.5477 g, 1.23 mmol) was transformed into the secondary amine 14c (crude yield 0.3587 g, 90%). Compound 14c (0.3587 mg, 1.11 mmol) was dissolved in THF (3 mL) and PhCH₂OCOCl (0.28 mL, 1.66 mmol) was added followed by NEt₃ (0.17 ml, 1.66 mmol). The residue was purified by fc (R_f 0.21). Colorless oil, yield 0.4881 g (86%). IR (neat): ν/cm⁻¹ = 1697 (s, C = O/Cbz C [double bond, length as m-dash]

O), 1206(s)/ 1082 (s, C–O–C). ¹H NMR (C₆D₅NO₂, 100 °C): δ (ppm) = 2.03–2.17 (m, 1H, 3-H), 2.12 (ddd, J = 16.3/6.6/3.0 Hz, 1H, 5-H), 2.23 (ddd, J = 15.7/7.2/2.8 Hz, 1H, 5-H), 2.45 (dt, J = 15.8/2.8 Hz, 1H, 6-H), 3.18–3.26 (m, 1H, 3-H), 3.61 (ddd, J = 15.0/ 8.5/3.5 Hz, 1H, 6-H), 3.64–3.67 (m, 1H, 2-H), 3.93–4.04 (m, 2H, OCH₂Ph), 4.31–4.36 (m,1H, OCH), 4.77 (dd, J = 12.6/2.8 Hz, 1H, OCH₂), 4.82 (dd, J = 12.6/3.0 Hz, 1H, OCH₂), 6.81–7.63 (m, 15 H, Ph). HRMS: calcd. for C₂₈H₂₇NO₅Na 480.1787, found 480.1781. HPLC (Method A): Purity 98%, t_R = 23.0 min.

(±)-Benzyl (2RS,4SR)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-hydroxypiperidine-1-carboxylate (16a) and (±)-Benzyl (2RS,4RS)-2-[(2SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-hydroxypiperidine-1-carboxylate (16b). According to General Procedure B compound 15a (0.2754 g, 0.6 mmol) was dissolved in MeOH (2 mL) and NaBH₄ (22 mg, 0.6 mmol) was added. The diastereomeric alcohols 16a and 16b were separated by fc.

Compound 16a (R_f 0.13): Colorless oil, yield 0.118 g (43%). IR (neat): ν/cm⁻¹ = 1670 (s, Cbz C [double bond, length as m-dash] O), 1204 (s)/1069 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.54–1.57 (m broad, 3H, 3-H + 5-H), 1.63–1.68 (m broad, 1H, 3-H), 1.91–1.95 (m broad, 1H, 6-H), 3.23 (ddd, J = 14.1/11.9/4.4 Hz, 1H, 6-H), 3.75–3.80 (m broad, 1H, 2-H), 3.92 (s broad, 1H, OH), 3.98–4.02 (m, 2H, OCH₂), 4.34–4.38 (m broad, 1H, 4-H), 4.46 (s broad, 1H, OCH), 4.98 (d, J = 12.1 Hz, 1H, OCH₂Ph), 5.09 (d, J = 12.4 Hz, 1H, OCH₂Ph), 7.17–7.27 (m, 10H, Ph), 7.36–7.42 (m, 5H, Ph). HRMS: calculated for C₂₈H₂₉NO₅Na 482.1938, found 482.1938. HPLC (Method A): Purity 98%, t_R = 22.19 min.

Compound 16b (R_f 0.08): Colorless oil, yield 0.125 g (45%). IR (neat): ν/cm⁻¹ = 1675 (s, Cbz C [double bond, length as m-dash] O), 1205 (s)/1070 (s, C–O–C). ¹H NMR (C₆D₅NO₂, 100 °C): δ (ppm) = 1.04 (qd, J = 12.6/4.8 Hz, 1H, 5-H), 1.29 (td, J = 12.5/6.3 Hz, 1H, 3-H), 1.53–1.59 (m broad, 2H, 3-H + 5-H), 1.81 (d, J = 4.7 Hz, 1H, OH), 2.83 (td, J = 13.5/2.6 Hz, 1H, 6-H), 3.49 (td, J = 7.7/2.2 Hz, 1H, 2-H), 3.71 (t broad, J = 7.3 Hz, 1H, OCH₂), 3.76–3.83 (m, 1H, 4-H), 3.88 (d broad, J = 13.7 Hz, 1H, 6-H), 4.05 (q, J = 7.0 Hz, 1H, OCH), 4.31 (t broad, J = 6.5 Hz, 1H, OCH₂), 4.69 (d, J = 12.7 Hz, 1H, OCH₂Ph), 4.82 (d, J = 12.7 Hz, 1H, OCH₂Ph), 6.78–7.63 (m, 15H, Ph). HRMS: calculated for C₂₈H₂₉NO₅Na 482.1938, found 482.1934. HPLC (Method A): Purity 95%, t_R = 21.6 min.

(±)-Benzyl (2RS,4SR)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-hydroxypiperidine-1-carboxylate (16c) and (±)-Benzyl (2RS,4RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-hydroxypiperidine-1-carboxylate (16d). According to General Procedure B compound 15c (0.1816 g, 0.4 mmol) was dissolved in MeOH (2 mL) and NaBH₄ (15 mg, 0.4 mmol) was added. The diastereomeric alcohols 16c and 16d were separated by fc.

Compound 16c (R_f 0.26): Colorless oil, yield 78.9 mg (43%). IR (neat): ν/cm⁻¹ = 1671 (s, Cbz C [double bond, length as m-dash] O), 1201(s) / 1049 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.19 (s broad, 2H, 3-H), 1.65–1.56 (m, 3H, 5-H + OH), 2.12 (d broad, J = 15.0 Hz, 1H, 6-H), 3.06–3.37 (m, 1H, 6-H), 3.87–3.91 (m broad, 3H, 2-H + 2OCH₂), 4.07 (s, 1H, 4-H), 4.13–4.77 (m, 1H, OCH), 5.00–5.07 (m, 2H, OCH₂Ph), 6.90–7.69 (m, 15H, Ph). HRMS: calculated for C₂₈H₂₉NO₅Na 482.1938, found 482.1935. HPLC (Method A): Purity 98%, t_R = 22.2 min.

Compound 16d (R_f 0.16): Colorless oil, yield 87.5 mg (47%). IR (neat): ν/cm⁻¹ = 1671 (s, Cbz C [double bond, length as m-dash] O), 1201 (s) / 1049 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.15–1.23 (m, 3H, 3-H + 5-H), 1.83 (s broad, 1H, OH), 2.33 (d broad, J = 10.8 Hz, 1H, 5-H), 2.69–3.07 (m, 1H, 6-H), 3.89 (s broad, 2H, 6-H + 2-H), 3.95–4.05 (m, 1H, 4-H), 4.05–4.19 (m, 1H, OCH₂), 4.19–4.27 (m, 1H, OCH₂), 4.28–4.52 (m, 1H, OCH), 5.03 (s broad, 2H, OCH₂Ph), 6.94–7.79 (m, 15H, Ph). HRMS: calculated for C₂₈H₂₉NO₅Na 482.1938, found 482.1930. HPLC (Method A): Purity 96%, t_R = 21.6 min.

(±)-(2RS,4SR)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-ol (17a). According to General Procedure F 16a (102.5 mg, 0.22 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 12.5 mg) was added. The product was purified by fc. Compound 17a (R_f 0.32): Colorless crystals, mp 126 °C, yield 58.2 mg (80%). IR (neat): ν/cm⁻¹ = 1067 (s, C–O–C), 697 (s, O–H). ¹H NMR (CDCl₃): δ (ppm) = 1.17 (q, J = 11.4 Hz, 1H, 3-H_ax), 1.36 (qd, J = 12.3/4.5 Hz, 1H, 5-H_ax), 1.68 (ddd, J = 9.8/4.4/2.2 Hz, 1H, 3-H), 1.87 (ddt, J = 12.1/4.4/2.1 Hz, 1H, 5-H), 2.31 (bs, 2H, NH, OH), 2.50–2.60 (m, 2H, 6-H), 3.07 (ddd, J = 12.0/4.1/2.7 Hz, 1H, 2-H), 3.54 (tt, J = 11.0/4.5 Hz, 1H, 4-H), 3.80–3.85 (m, 1H, OCH₂), 3.96–4.01 (m, 2H, OCH₂ + OCH), 7.22–7.30 (m, 6H, Ph), 7.42–7.49 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 35.9 (C-5), 38.0 (C-3), 44.2 (C-6), 58.3 (C-2), 67.4 (OCH₂), 69.2 (C-4), 80.1 (OCH), 110.1 (OCO), 126.3 (Ph-C), 126.5 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 142.1 (Ph-C), 142.4 (Ph-C). HRMS: calculated for C₂₀H₂₃NO₃H 326.1751, found 326.1749. HPLC (Method A): Purity 99%, t_R = 15.8 min.

(±)-(2RS,4RS)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-ol (17b). According to General Procedure F 16b (91.9 mg, 0.20 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 9.5 mg) was added. The product was purified by fc. Compound 17b (R_f 0.21): Colorless oil, 48.9 mg (75%). IR (neat): ν/cm⁻¹ = 1067 (s, C–O–C), 696 (s, O–H bending). ¹H NMR (CDCl₃): δ (ppm) = 1.37 (ddd, J = 13.3/11.1/2.9 Hz, 1H, 3-H_ax), 1.46 (ddd, J = 13.2/5.0/3.2 Hz, 1H, 3-H), 1.62 (dq, J = 13.0/2.8 Hz, 1H, 5-H), 1.70 (tdd, J = 12.2/4.4/2.8 Hz, 1H, 5-H), 2.19 (s broad, 2H, NH + OH), 2.83 (ddd, J = 11.4/4.6/2.8 Hz, 1H, 6-H), 2.95–3.05 (m, 2H, 2-H + 6-H), 3.79–3.85 (m, 1H, OCH₂), 3.91–3.95 (m, 1H, OCH₂), 3.97 (q, J = 5.5 Hz, 1H, OCH), 4.10 (quint, J = 3.1 Hz, 1H, 4-H), 7.24–7.34 (m, 6H, Ph), 7.42–7.49 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 32.9 (C-5), 35.1 (C-3), 39.8 (C-6), 53.5 (C-2), 64.0 (C-4), 67.0 (OCH₂), 79.9(OCH), 109.6 (OCO), 126.1 (Ph-C), 126.2 (Ph-C), 127.9 (Ph-C), 128.0 (Ph-C), 128.1 (Ph-C), 141.8 (Ph-C), 142.0 (Ph-C). HRMS: calculated for C₂₀H₂₃NO₃H 326.1751, found 326.1742. HPLC (Method A): Purity 99%, t_R = 16.2 min.

(±)-(2RS,4SR)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-ol (17c). According to General Procedure F 16c (112.4 mg, 0.24 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 13.0 mg) was added. The product was purified by fc. Compound 17c (R_f 0.11): Colorless oil, yield 70.0 mg (88%). IR (neat): ν/cm⁻¹ = 1067 (s, C–O–C), 697 (s, O–H). ¹H NMR (CDCl₃): δ (ppm) = 1.01 (q, J = 11.4 Hz, 1H, 3-H_ax), 1.31 (qd, J = 12.4/4.5 Hz, 1H, 5-H), 1.86 (ddd, J = 12.1/4.2/2.0 Hz, 1H, 5-H), 1.99 (dt, J = 12.0/2.0 Hz, 1H, 3-H), 2.07 (s broad, 2H, NH + OH), 2.54 (td, J = 12.4/2.0, 1H, 6-H), 2.80 (ddd, J = 11.6/4.3/2.3 Hz, 1H, 2-H), 3.05 (ddd, J = 12.3/4.0/2.5 Hz, 1H, 6-H), 3.57 (tt, J = 10.8/4.4 Hz, 1H, 4-H), 3.92 (t, J = 7.2 Hz, 1H, OCH₂), 4.03 (td, J = 6.7/4.5 Hz, 1H, OCH), 4.11 (t, J = 7.2 Hz, 1H, OCH₂), 7.22–7.30 (m, 6H, Ph), 7.44–7.51 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 35.7 (C-5), 37.7 (C-3), 44.1 (C-6), 56.4 (C-2), 65.8 (OCH₂), 68.8 (C-4), 78.9 (OCH), 109.5 (OCO), 125.9 (Ph-C), 126.1 (Ph-C), 127.9 (Ph-C), 128.0 (Ph-C), 128.1 (Ph-C), 128.2 (Ph-C), 141.7 (Ph-C), 141.9 (Ph-C). HRMS: calculated for C₂₀H₂₃NO₃H 326.1751, found 326.1745. HPLC (Method A): Purity 97%, t_R = 15.6 min.

(±)-(2RS,4RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-ol (17d, WMS-2508). According to General Procedure F 16d (119.9 mg, 0.26 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 12.00 mg) was added. The product was purified by fc. Compound 17d (R_f 0.09): Colorless crystals, mp 126 °C, yield 75.3 mg (89%). IR (neat): ν/cm⁻¹ = 1066 (s, C–O–C), 698 (s, O–H). ¹H NMR (CDCl₃): δ (ppm) = 1.40 (ddd, J = 11.9/9.0/2.5 Hz, 1H, 3-H), 1.56 (bs, 2H, NH + OH), 1.60–1.71 (m, 2H, 3-H, 5-H), 1.74 (ddd, J = 8.1/5.4/3.2 Hz, 1H, 2-H), 2.84 (ddd, J = 12.2/4.4/3.0 Hz, 1H, 5-H), 3.02 (td, J = 12.0/3.6 Hz, 1H, 6-H), 3.26 (ddd, J = 11.7/4.1/2.8 Hz, 1H, 6-H), 3.93 (t, J = 7.1 Hz, 1H, OCH₂), 4.05 (td, J = 6.5/4.6 Hz, 1H, OCH), 4.12 (t, J = 7.0 Hz, 1H, OCH₂), 4.20 (quint, J = 3.1 Hz, 1H, 4-H), 7.26–7.36 (m, 7H, Ph), 7.46–7.54 (m, 3H, Ph). HRMS: calculated for C₂₀H₂₃NO₃H 326.1751, found 326.1747. HPLC (Method A): Purity 96%, t_R = 16.1 min.

A sample of compound 17d was recrystallized with n-hexane–CH₂Cl₂ mixture and the resulting crystals were used for the X-ray crystal structure analysis.

X-Ray crystal structure analysis of 17d. Formula C₂₀H₂₃NO₃, M = 325.39, colorless crystal 0.20 × 0.15 × 0.05 mm, a = 6.2254(4), b = 33.9225(23), c = 8.1729(6) Å, β = 97.459(2)°, V = 1711.4(2) Å³, ρ_c = 1.263 g cm⁻³, μ = 6.77 cm⁻¹, empirical absorption correction (0.8764 ≤ T ≤ 0.9669), Z = 4, monoclinic, space group P2₁/n (No. 14), λ = 1.54178 Å, T = 223(2) K, ω and φ scans, 5702 reflections collected (±h, ±k, ±l), [(sinθ)/λ] = 0.58 Å⁻¹, 2001 independent (R_int = 0.055) and 1472 observed reflections [I ≥ 2 σ(I)], 222 refined parameters, R = 0.064, wR² = 0.171, max. (min.) residual electron density 0.23(−0.23) e Å⁻³, hydrogen atoms calculated and refined as riding atoms.

Data set was collected with a Nonius KappaCCD diffractometer. Programs used: data collection COLLECT (Nonius B.V., 1998), data reduction Denzo-SMN (Z. Otwinowski and W. Minor, Methods in Enzymology, 1997, 276, 307–326), absorption correction Denzo (Z. Otwinowski, D. Borek, W. Majewski and W. Minor, Acta Crystallogr., 2003, A59, 228–234), structure solution SHELXS-97 (G. M. Sheldrick, Acta Crystallogr., 1990, A46, 467–473), structure refinement SHELXL-97 (G. M. Sheldrick, Acta Crystallogr., 2008, A64, 112–122), graphics SCHAKAL (E. Keller, Universität Freiburg, 1997).

CCDC 750839 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge at http://www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (internet.) +44(1223)336-033, E-mail: mailto:deposit@ccdc.cam.ac.uk]

(±)-Benzyl (2RS,4SR)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine-1-carboxylate (18a). According to General Procedure C compound 16a (76.5 mg, 0.16 mmol) was dissolved in DMF (2 mL) and NaH (7.00 mg, 0.32 mmol) was added followed by MeI (0.01 mL, 0.16 mmol). The product was purified by fc. Compound 18a (R_f 0.40): Colorless oil, yield 64.8 mg (85%). IR (neat): ν/cm⁻¹ = 1694 (s, Cbz C [double bond, length as m-dash]

O), 1080 (s, O–CH₃), 1205 (s) / 1027 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.44–1.49 (m, 1H, 3-H), 1.51–1.53 (m, 1H, 5-H), 1.68 (ddd, J = 14.7/6.3/3.1 Hz, 1H, 3-H), 1.77 (d broad, J = 14.0 Hz, 1H, 5-H), 3.14 (s, 3H, OCH₃), 3.20 (d broad, J = 13.2 Hz, 1H, 6-H), 3.39–3.41 (m, 1H, 2-H), 3.64 (t, J = 7.6 Hz, 1H, OCH₂), 3.97 (d broad, J = 13.8 Hz, 1H, 6-H), 4.04 (t, J = 7.2 Hz, 1H, OCH₂), 4.30–4.34 (m 1H, 4-H), 4.74 (dt, J = 9.5/6.9 Hz, 1H, OCH), 4.86 (s broad, 1H, OCH₂Ph), 5.13 (d, J = 12.5 Hz, 1H, OCH₂Ph), 7.12–7.42 (m, 15H, Ph). HRMS: calculated for C₂₉H₃₁NO₅Na 496.2094, found 496.2099. HPLC (Method B): Purity 98%, t_R = 21.5 min.

(±)-Benzyl (2RS,4RS)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine-1-carboxylate (18b). According to General Procedure C compound 16b (69.9 mg, 0.15 mmol) was dissolved in DMF (2 mL) and NaH (7.00 mg, 0.32 mmol) was added followed by MeI (0.01 mL, 0.16 mmol). The product was purified by fc. Compound 18b (R_f 0.33): Colorless oil, yield 57.1 mg (80%). IR (neat): ν/cm⁻¹ = 1693 (s, Cbz C [double bond, length as m-dash]

O), 1092 (s, O–CH₃), 1205(s) / 1026 (s, C–O–C). ¹H NMR (C₆D₅NO₂, 100 °C): δ (ppm) = 0.84–0.96 (m, 1H, 5-H), 1.18 (ddd, J = 13.4/4.7/2.5 Hz, 1H, 5-H), 1.55 (d broad, J = 13.2 Hz, 2H, 3-H), 2.70–2.81 (m,1H, 6-H), 2.84 (s, 3H, OCH₃), 3.22–3.34 (m, 1H, 2-H), 3.49 (t, J = 7.8 Hz, 1H, OCH₂), 3.69–3.73 (m,1H, OCH), 3.85 (d broad, J = 13.5 Hz, 1H, 6-H), 4.01–4.07 (m, 1H, OCH₂), 4.26–4.30 (m, 1H, 4-H), 4.69 (d, J = 12.7 Hz, 1H, OCH₂Ph), 4.82 (d, J = 12.7 Hz, 1H, OCH₂Ph), 6.79–7.18 (m, 15H, -Ph). HRMS: calculated for C₂₉H₃₁NO₅Na 496.2094, found 496.2090. HPLC (Method B): Purity 99%, t_R = 21.2 min.

(±)-Benzyl (2RS,4SR)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine-1-carboxylate (18c). According to General Procedure C compound 16c (77.8 mg, 0.17 mmol) was dissolved in DMF (2 mL) and NaH (8 mg, 0.34 mmol) was added followed by MeI (0.01 mL, 0.17 mmol). The product was purified by fc. Compound 18c (R_f 0.58): Colorless oil, yield 74.8 mg (93%). IR (neat): ν/cm⁻¹ = 1695 (s, Cbz C [double bond, length as m-dash]

O), 1085 (s, O–CH₃), 1205 (s) / 1027 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.56 (ddd, J = 13.3/4.6/2.9 Hz, 1H, 3-H), 1.66–1.80 (m, 2H, 3-H + 5-H), 2.41 (d broad, J = 13.9 Hz, 1H, 5-H), 2.89–3.11 (m, 1H, 6-H), 3.37 (s, 3H, OCH₃), 3.51–3.54 (m, 1H, 6-H), 3.84–3.85 (m broad, 3H, OCH₂ + 2-H), 4.08–4.29 (m, 1H, 4-H), 4.62–4.84 (m, 1H, OCH), 5.04 (s, 2H, OCH₂Ph), 6.80–7.63 (m, 15H, Ph). HRMS: calculated for C₂₉H₃₁NO₅Na 496.2094, found 496.2093. HPLC (Method A): Purity 98%, t_R = 25.16 min.

(±)-Benzyl (2RS,4RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine-1-carboxylate (18d). According to General Procedure C compound 16d (102.6 mg, 0.22 mmol) was dissolved in DMF (2 mL) and NaH (10 mg, 0.44 mmol) was added followed by MeI (0.013 mL, 0.22 mmol). The product was purified by fc. Compound 18d (R_f 0.55): Colorless oil, yield 94.1 mg (91%). IR (neat): ν/cm⁻¹ = 1696 (s, Cbz C [double bond, length as m-dash]

O), 1092 (s, O–CH₃), 1205 (s) / 1027 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.22–1.27 (m, 1H, 3-H), 1.31 (s broad, 1H, 5-H), 1.82–2.01 (m, 1H, 3-H), 1.87–1.97 (m broad, 1H, 5-H), 2.72–3.06 (m, 1H, 6-H), 3.17 (s, 3H, OCH₃), 3.52 (tt, J = 11.2/4.5 Hz, 1H, 4-H), 3.82–3.90 (m broad, 2H, 6-H + 2-H), 4.11–4.18 (m, 1H, OCH₂), 4.25 (q, J = 6.7 Hz, 1H, OCH), 4.28–4.49 (m, 1H, OCH₂), 5.04 (s, 2H, OCH₂Ph), 6.84–7.67 (m, 15H, Ph). HRMS: calculated for C₂₉H₃₁NO₅Na 496.2094, found 496.2093. HPLC (Method A): Purity 98%, t_R = 24.48 min.

(±)-(2RS,4SR)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine (19a). According to General Procedure F 18a (73.1 mg, 0.16 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 7.0 mg) was added. The product was purified by fc. Compound 19a (R_f 0.46): Colorless oil, yield 40.8 mg (78%). IR (neat): ν/cm⁻¹ = 1067 (s, C–O–C), 1085 (s, O–CH₃). ¹H NMR (CDCl₃): δ (ppm) = 1.02 (q, J = 11.5 Hz, 1H, 3-H_ax), 1.26 (qd, J = 12.4/4.4 Hz, 1H, 5-H), 1.72 (ddt, J = 11.8/4.2/2.1 Hz, 1H, 5-H), 1.94 (ddd, J = 12.3/4.3/2.2 Hz, 1H, 3-H), 2.03 (s broad, 1H, NH), 2.47–2.57 (m, 2H, 6-H, 2-H), 3.05–3.13 (m, 2H, 6-H, 4-H), 3.25 (s, 3H, OCH₃), 3.78–3.84 (m, 1H, OCH₂), 3.93–3.99 (m, 2H, OCH, OCH₂), 7.18–7.27 (m, 6H, Ph), 7.38–7.45 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 32.1 (C-5), 34.6 (C-3), 44.2 (C-6), 55.7 (OCH₃), 58.4 (C-2), 67.3 (OCH₂), 77.7 (C-4), 80.2 (OCH), 110.1 (OCO), 126.3 (Ph-C), 126.5 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 142.2 (Ph-C), 142.4 (Ph-C). HRMS: calculated for C₂₁H₂₅NO₃H 340.1907, found 340.1908. HPLC (Method A): Purity 95%, t_R = 16.9 min.

(±)-(2RS,4RS)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine (19b). According to General Procedure F 18b (57.1 mg, 0.12 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 5.0 mg) was added. The product was purified by fc. Compound 19b (R_f 0.23): Colorless oil, yield 36.8 mg (90%). IR (neat): ν/cm⁻¹ = 1069 (s, C–O–C), 1085 (s, O–CH₃). ¹H NMR (CDCl₃): δ (ppm) = 1.32 (ddd, J = 13.3/10.9/2.8 Hz, 1H, 3-H_ax), 1.55 (dddd, J = 13.3/12.4/4.7/2.3 Hz, 1H, 5-H), 1.62 (ddd, J = 13.9/5.7/2.8 Hz, 1H, 3-H), 1.85 (ddt, J = 13.9/5.2/2.6 Hz, 1H, 5-H), 2.24 (bs, 1H, NH), 2.85 (ddd, J = 11.6/4.7/2.5 Hz, 1H, 6-H), 2.92–3.02 (m, 2H, 6-H + 2-H), 3.29 (s, 3H, OCH₃), 3.57 (quint, J = 3.0 Hz, 1H, 4-H), 3.87 (t, J = 6.8 Hz, 1H, OCH₂), 3.95 (q, J = 6.8 Hz, 1H, OCH), 4.01 (t, J = 6.8 Hz, 1H, OCH₂) 7.18–7.27 (m, 6H, Ph), 7.38–7.45 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 29.2 (C-5), 32.3 (C-3), 40.2 (C-6), 53.7 (C-2), 55.6 (OCH₃), 67.1 (OCH₂), 73.1 (C-4), 80.1 (OCH), 109.8 (OCO), 126.2 (Ph-C), 126.3 (Ph-C), 127.9 (Ph-C), 128.0 (Ph-C), 128.1 (Ph-C), 141.9 (Ph-C), 142.0 (Ph-C). HRMS: calculated for C₂₁H₂₅NO₃H 340.1907, found 340.1901. HPLC (Method A): Purity 97%, t_R = 17.4 min.

(±)-(2RS,4SR)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine (19c). According to General Procedure F 18c (58.7 mg, 0.12 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 6.0 mg) was added. The product was purified by fc. Compound 19c (R_f 0.41): Colorless oil, yield 34.2 mg (81%). IR (neat): ν/cm⁻¹ = 1068 (s, C–O–C), 1087 (s, O–CH₃). ¹H NMR (CDCl₃): δ (ppm) = 0.91 (q, J = 11.6 Hz, 1H, 3-H_ax), 1.21 (qd, J = 12.3/4.4 Hz, 1H, 5-H), 1.55 (s broad, 1H, -NH), 1.93 (ddd, J = 12.2/4.2/2.1 Hz, 1H, 5-H), 2.04 (dt, J = 11.9/2.2 Hz, 1H, 3-H), 2.49 (td, J = 12.4/2.5 Hz, 1H, 6-H), 2.77 (ddd, J = 11.7/4.3/2.3 Hz,1H, 6-H), 3.04 (ddd, J = 12.3/4.1/3.0, 1H, 2-H), 3.11 (tt, J = 10.9/4.3 Hz, 1H, 4-H), 3.27 (s, 3H, OCH₃), 3.87 (t, J = 7.2 Hz, 1H, OCH₂), 3.98 (td, J = 6.8/4.6 Hz, 1H, OCH), 4.08 (t, J = 6.7 Hz, 1H, OCH₂) 7.18–7.27 (m, 6H, Ph), 7.39–7.47 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 32.7 (C-5), 34.8 (C-3), 44.5 (C-6), 55.7 (OCH₃), 56.8 (C-2), 66.2 (OCH₂), 77.9 (C-4), 79.5 (OCH), 109.8 (OCO), 126.3 (Ph-C), 126.5 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 128.5 (Ph-C), 142.2 (Ph-C), 142.3 (Ph-C). HRMS: calculated for C₂₁H₂₅NO₃H 340.1907, found 340.1907. HPLC (Method A): Purity 94%, t_R = 16.2 min.

(±)-(2RS,4RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methoxypiperidine (19d). According to General Procedure F 18d (94.1 mg, 0.19 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 9.0 mg) was added. The product was purified by fc. Compound 19d (R_f 0.23): Colorless oil, yield 52.3 mg (77%). IR (neat): ν/cm⁻¹ = 1205/1068 (s, C–O–C), 1087 (s, O–CH₃). ¹H NMR (CDCl₃): δ (ppm) = 1.28 (ddd, J = 13.1/11.4/2.7 Hz, 1H, 3-H), 1.55 (dddd, J = 13.7/12.4/4.8/2.7 Hz, 1H, 5-H), 1.75 (s broad, 1H, NH), 1.82 (dtd, J = 13.9/5.1/2.4 Hz, 1H, 5-H), 1.94 (ddd, J = 13.4/5.2/2.4 Hz, 1H, 3-H), 2.82 (ddd, J = 12.0/4.7/2.4 Hz, 1H, 6-H), 2.95 (td, J = 12.3/2.7 Hz, 1H, 6-H), 3.19 (ddd, J = 11.7/4.2/2.6 Hz, 1H, 2-H), 3.30 (s, 3H, OCH₃), 3.60 (quint, J = 2.9 Hz, 1H, 4-H), 3.95 (t, J = 7.0 Hz, 1H, OCH₂), 4.05 (td, J = 6.5/4.5 Hz, 1H, OCH), 4.11 (t, J = 6.5 Hz, 1H, OCH₂), 7.24–7.36 (m, 6H, Ph), 7.47–7.55 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 30.2 (C-5), 31.9 (C-3), 41.0 (C-6), 52.3 (OCH₃), 55.9 (C-2), 66.2 (OCH₂), 73.6 (C-4), 79.7 (OCH), 109.8 (OCO), 126.4(Ph-C), 126.5 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 128.5 (Ph-C), 142.3 (Ph-C), 142.5 (Ph-C). HRMS: calculated for C₂₁H₂₅NO₃H 340.1907, found 340.1905. HPLC (Method A): Purity 98%, t_R = 17.7 min.

(±)-Benzyl (2RS,4SR)-4-Benzylamino-2-[(4SR)-2,2-diphenyl-1,3-dioxolan-4-yl] piperidine-1-carboxylate (20a) and (±)-Benzyl (2RS,4RS)-4-Benzylamino-2-[(4SR)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine-1-carboxylate (20b). According to General Procedure D compound 15a (0.103 g, 0.22 mmol) dissolved in CH₂Cl₂ (2 mL) was reacted with benzylamine (0.04 mL, 0.33 mmol) and NaBH(OAc)₃ (70 mg, 0.33 mmol). The diastereomeric amines 20a and 20b were separated by fc.

Compound 20a (R_f 0.62): Colourless oil, yield 66.7 mg (58%). IR (neat): ν/cm⁻¹ = 1690 (s, Cbz C [double bond, length as m-dash] O), 1205 (s)/1086 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.27–1.32 (m, 1H, 3-H), 1.55–1.61 (m broad, 3H, 3-H + 5-H), 1.78–1.87 (m, 1H, 6-H), 1.93 (ddd, J = 14.0/6.0/3.9 Hz, 1H, 2-H), 2.97 (quint, J = 4.3 Hz, 1H, 4-H), 3.42 (td, J = 11.9/3.3 Hz, 1H, 6-H), 3.68 (d, J = 13.0 Hz, 1H, CH₂Ph), 3.73 (d, J = 13.0 Hz, 1H, CH₂Ph), 3.89 (t, J = 7.4 Hz, 1H, OCH₂), 3.95 (s, 1H, NH), 4.05 (t, J = 7.4 Hz, 1H, OCH₂), 4.36 (q, J = 6.8 Hz, 1H, OCH), 5.05 (d, J = 12.4 Hz, 1H, OCH₂Ph), 5.22 (d, J = 12.5 Hz, 1H, OCH₂Ph), 7.15–7.57 (m, 20H, Ph). HRMS: calculated for C₃₅H₃₆N₂O₄H 549.2748, found 549.2743. HPLC (Method A): Purity 98%, t_R = 21.6 min.

Compound 20b (R_f 0.25): Colourless oil, yield 33.5 mg (29%). IR (neat): ν/cm⁻¹ = 1688 (s, Cbz C [double bond, length as m-dash] O), 1205 (s)/1070 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.20–1.29 (m broad, 1H, 3-H), 1.51 (s broad, 3H, 3-H + 5-H + NH), 1.73–1.76 (m broad, 1H, 5-H), 1.91–1.96 (m broad, 1H, 6-H), 2.97–3.17 (m, 2H, 6-H + 4-H), 3.77–3.83 (m broad, 3H, 2-H + CH₂Ph), 4.00 (s broad, 1H, OCH₂), 4.27–4.30 (m broad, 2H, OCH + OCH₂), 4.89(d broad, J = 10.5 Hz, 1H, OCH₂Ph), 5.15 (d, J = 11.8 Hz, 1H, OCH₂Ph), 7.22–7.45 (m, 20H, Ph). HRMS: calculated for C₃₅H₃₆N₂O₄H 549.2748, found 549.2743. HPLC (Method A): Purity 97%, t_R = 20.4 min.

(±)-Benzyl (2RS,4SR)-4-Benzylamino-2-[(4RS)-2,2-diphenyl-1,3-dioxolan-4-yl] piperidine-1-carboxylate (20c) and (±)-Benzyl (2RS,4RS)-4-Benzylamino-2-[(4RS)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine-1-carboxylate (20d). According to General Procedure E compound 15c (0.129 g, 0.28 mmol) dissolved in trimethyl orthoformate (2 mL) was reacted with benzylamine (0.05 mL, 0.42 mmol) added. Then NaBH₄ (16 mg, 0.42 mmol) was added. The diastereomeric amines 20c and 20d were separated by fc.

Compound 20c (R_f 0.52): Colourless oil, yield 90.6 mg (59%). IR (neat): ν/cm⁻¹ = 1693 (s, Cbz C [double bond, length as m-dash] O), 1203 (s)/1087 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.17–1.20 (m, 1H, 3-H), 1.31–1.36 (m, 1H, 3-H), 1.46–1.62 (m broad, 2H, 5-H), 1.69 (d broad, J = 13.0 Hz, 1H, 6-H), 2.07 (d broad, J = 14.3 Hz, 1H, 6-H), 2.97 (quint, J = 3.7 Hz, 1H, 4-H), 3.20–3.29 (m broad, 1H, 2-H), 3.69 (d, J = 13.0 Hz, 1H, CH₂Ph), 3.81 (d, J = 13.0 Hz, 1H, CH₂Ph), 3.83–3.92 (m, 2H, NH + OCH₂), 4.04–4.10 (m, 1H, OCH), 4.91–4.95 (m, 1H, OCH₂), 4.98–5.07 (m, 2H, OCH₂Ph), 7.08–7.26 (m, 15H, Ph), 7.32–7.38 (m, 5H, Ph). HRMS: calculated for C₃₅H₃₆N₂O₄H 549.2748, found 549.2743. HPLC (Method A): Purity 97%, t_R = 22.6 min.

Compound 20d (R_f 0.10): Colourless oil, yield 56.3 mg (37%). IR (neat): ν/cm⁻¹ = 1697 (s, Cbz C [double bond, length as m-dash] O), 1204 (s)/1070 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.21–1.28 (m broad, 2H, 3-H + NH), 1.31–1.39 (m broad, 2H, 3-H + 5-H), 1.84–1.91 (m broad, 1H, 5-H), 2.44 (d broad, J = 12.9 Hz, 1H, 6-H), 2.77–3.02 (m broad, 2H, 6-H + 4-H), 3.79 (d broad, J = 14.9 Hz, 2H, CH₂Ph), 3.87–3.99 (m broad, 2H, 2-H + OCH₂), 4.22–4.37 (m broad, 2H, OCH + OCH₂), 5.11 (s broad, 2H, OCH₂Ph), 7.27–7.47 (m, 20H, Ph). HRMS: calculated for C₃₅H₃₆N₂O₄H 549.2748, found 549.2741. HPLC (Method A): Purity 92%, t_R = 22.0 min.

(±)-(2RS,4SR)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-amine (21a). According to General Procedure F 20a (66.7 mg, 0.12 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 7.0 mg) was added. The product was purified by fc. Compound 21a (R_f 0.30): Colourless oil, yield 35.0 mg (89%). IR (neat): ν/cm⁻¹ = 1067 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 0.94 (q, J = 11.5 Hz, 1H, 3-H_ax), 1.22 (qd, J = 12.3/4.2 Hz, 1H, 5-H_ax), 1.57–1.62 (m, 1H, 3-H), 1.79 (s broad, 4H, 5-H + NH₂ + NH), 2.56–2.64 (m, 2H, 6-H + 2-H), 2.65–2.70 (m, 1H, 4-H), 3.09 (ddd, J = 12.4/2.5/1.2 Hz, 1H, 6-H), 3.86 (t, J = 6.3 Hz, 1H, OCH₂), 3.97 (t, J = 6.9 Hz, 1H, OCH₂), 4.02 (q, J = 7.0 Hz, 1H, OCH), 7.24–7.33 (m, 6H, Ph), 7.45–7.52 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 36.8 (C-5), 38.9 (C-3), 45.1 (C-6), 49.2 (C-4), 58.9 (C-2), 67.4 (OCH₂), 80.3 (OCH), 110.0 (OCO), 126.3 (Ph-C), 126.5 (Ph-C), 127.9 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 142.2 (Ph-C), 142.4 (Ph-C). HRMS: calculated for C₂₀H₂₄N₂O₂H 325.1911, found 325.1921. HPLC (Method A): Purity 96%, t_R = 13.9 min.

(±)-(2RS,4RS)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-amine (21b). According to General Procedure F 20b (33.5 mg, 0.06 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 4.0 mg) was added. The product was purified by fc. Compound 21b (R_f 0.31): Colourless oil, 17.0 mg (87%). IR (neat): ν/cm⁻¹ = 1069 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.24–1.29 (m, 1H, 3-H), 1.35–1.42 (m, 2H, 3-H + 5-H), 1.71 (tdd, J = 13.2/4.2/1.8 Hz, 1H, 5-H), 1.82 (s broad, 3H, NH + NH₂), 2.80 (dt, J = 11.9/4.2 Hz, 1H, 6-H), 2.85–2.94 (m, 2H, 2-H + 6-H), 3.16 (quint, J = 3.9 Hz, 1H, 4-H), 3.72–3.78 (m, 1H, OCH₂), 3.93–4.00 (m, 2H, OCH₂ + OCH), 7.19–7.27 (m, 6H, Ph), 7.38–7.45 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 33.8 (C-5), 35.8 (C-3), 39.9 (C-6), 44.2 (C-4), 53.9 (C-2), 67.5 (OCH₂), 79.6 (OCH), 110.1 (OCO), 126.4 (Ph-C), 126.5 (Ph-C), 126.6 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 128.5 (Ph-C), 142.2 (Ph-C), 142.4 (Ph-C). HRMS: calculated for C₂₀H₂₄N₂O₂H 325.1911, found 325.1919. HPLC (Method A): Purity 93%, t_R = 13.6 min.

(±)-(2RS,4SR)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-amine (21c). According to General Procedure F 20c (90.6 mg, 0.16 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 9.0 mg) was added. The product was purified by fc. Compound 21c (R_f 0.30): Colourless oil, yield 49.2 mg (91%). IR (neat): ν/cm⁻¹ = 1067 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 0.86 (q, J = 11.5 Hz, 1H, 3-H_ax), 1.16 (qd, J = 12.1/4.0 Hz, 1H, 5-H_ax), 1.76 (d broad, J = 10.9 Hz, 1H, 3-H), 1.87 (d broad, J = 12.1 Hz, 1H, 5-H), 2.50 (td, J = 11.1/2.3 Hz, 1H, 6-H), 2.68 (tt, J = 11.3/4.0 Hz, 1H, 4-H), 2.77 (ddd, J = 11.7/4.4/2.0 Hz, 1H, 6-H), 2.87 (s broad, 3H, NH₂ + NH), 2.99 (ddd, J = 12.3/4.7/2.2 Hz, 1H, 2-H), 3.85 (t, J = 7.0 Hz, 1H, OCH₂), 3.96 (td, J = 6.4/4.5 Hz, 1H, OCH), 4.06 (t, J = 6.6 Hz, 1H, OCH₂), 7.18–7.29 (m, 6H, Ph), 7.38–7.45 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 35.7 (C-5), 37.8 (C-3), 44.9 (C-6), 49.1 (C-4), 56.9 (C-2), 65.9 (OCH₂), 79.1 (OCH), 109.6 (OCO), 126.0 (Ph-C), 126.2 (Ph-C), 128.0 (Ph-C), 128.1 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 141.9 (Ph-C), 142.0 (Ph-C). HRMS: calculated for C₂₀H₂₄N₂O₂H 325.1911, found 325.1911. HPLC (Method B): Purity 98%, t_R = 11.2 min.

(±)-(2RS,4RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidin-4-amine (21d). According to General Procedure F 20d (56.3 mg, 0.10 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 6.0 mg) was added. The product was purified by fc. Compound 21d (R_f 0.21): Colourless oil, 27.0 mg (83%). IR (neat): ν/cm⁻¹ = 1069 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.37–1.43 (m, 1H, 3-H), 1.49–1.52 (m, 2H, 3-H + 5-H), 1.60 (s broad, 3H, NH + NH₂), 1.67–1.75 (m, 1H, 5-H),, 2.79 (dt, J = 12.4/4.2 Hz, 1H, 6-H), 2.94 (td, J = 12.0/3.0 Hz, 1H, 6-H), 3.15–3.19 (m, 1H, 2-H), 3.30 (quint, J = 3.7 Hz, 1H, 4-H), 3.94 (t, J = 6.5 Hz, 1H, OCH₂), 4.03–4.11 (m, 2H, OCH₂ + OCH), 7.25–7.34 (m, 6H, Ph), 7.44–7.52 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 34.2 (C-5), 36.1 (C-3), 40.5 (C-6), 44.3 (C-4), 52.2 (C-2), 66.6 (OCH₂), 79.3 (OCH), 109.7 (OCO), 126.3 (Ph-C), 126.5 (Ph-C), 126.6 (Ph-C), 128.0 (Ph-C), 128.1 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 142.3 (Ph-C), 142.5 (Ph-C). HRMS: calculated for C₂₀H₂₄N₂O₂H 325.1911, found 325.1919. HPLC (Method A): Purity 94%, t_R = 14.0 min.

(±)-Benzyl (2RS,4SR) -2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methylaminopiperidine-1-carboxylate (22a) and (±)-Benzyl (2RS,4RS)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methylaminopiperidine-1-carboxylate (22b). According to General Procedure D compound 15a (0.143 g, 0.31 mmol) was dissolved in CH₂Cl₂ (2 mL) and 2M solution of methylamine in THF (0.23 mL, 0.47 mmol) was added followed by NaBH(OAc)₃ (99 mg, 0.47 mmol). The diastereomeric amines 22a and 22b were separated by fc.

Compound 22a (R_f 0.55): Colourless oil, yield 94.5 mg (64%). IR (neat): ν/cm⁻¹ = 1688 (s, Cbz C [double bond, length as m-dash] O), 1207 (s)/1090 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.25–1.31 (m, 1H, 3-H), 1.44–1.55 (m, 2H, 3-H + 5-H), 1.77–1.85 (m, 1H, 5-H), 1.89 (ddd, J = 13.6/6.1/3.8 Hz, 1H, 6-H), 2.34 (s, 3H, NCH₃), 2.72 (quint, J = 5.0 Hz, 1H, 4-H), 3.37 (td, J = 12.8/3.8 Hz, 1H, 6-H), 3.85 (s broad, 1H, NH), 3.89 (t, J = 7.4 Hz, 1H, OCH₂), 4.04 (t, J = 7.2 Hz, 1H, OCH₂), 4.28 (q, J = 6.2 Hz, 1H, 2-H), 4.79 (q, J = 6.7 Hz, 1H, OCH), 5.01 (d, J = 12.5 Hz, 1H, OCH₂Ph), 5.18 (d, J = 12.5 Hz, 1H, OCH₂Ph), 7.23–7.35 (m, 10H, Ph), 7.47–7.53 (m, 5H, Ph). HRMS: calculated for C₂₉H₃₂N₂O₄H 473.2435, found 473.2437. HPLC (Method A): Purity 96%, t_R = 19.2 min.

Compound 22b (R_f 0.23): Colourless oil, yield 37.6 mg (26%). IR (neat): ν/cm⁻¹ = 1693 (s, Cbz C [double bond, length as m-dash] O), 1208 (s)/1070 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.15–1.17 (m broad, 1H, 3-H), 1.42–1.46 (m broad, 1H, 5-H), 1.73 (d broad, J = 11.1 Hz, 1H, 3-H), 1.91 (s broad, 2H, 5-H + NH), 2.42 (s, 3H, NCH₃), 2.78 (s broad, 1H, 6-H), 2.93–3.10 (m broad, 2H, 6-H + 4-H), 3.85 (s broad, 1H, 2-H), 4.06 (t broad, J = 6.3 Hz, 1H, OCH₂), 4.28–4.36 (m broad, 2H, OCH + OCH₂), 4.87 (d, J = 11.6 Hz, 1H, OCH₂Ph), 5.16 (d, J = 10.6 Hz, 1H, OCH₂Ph), 7.22–7.36 (m, 10H, Ph), 7.44–7.51 (m, 5H, Ph). HRMS: calculated for C₂₉H₃₂N₂O₄H 473.2435, found 473.2430. HPLC (Method A): Purity 98%, t_R = 19.7 min.

(±)-Benzyl (2RS,4SR)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methylaminopiperidine-1-carboxylate (22c) and (±)-Benzyl (2RS,4RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-4-methylaminopiperidine-1-carboxylate (22d). According to General Procedure E compound 15c (0.143 g, 0.31 mmol) was dissolved in trimethyl orthoformate (2 mL) and 2M solution of methylamine in THF (0.03 mL, 0.47 mmol) was added. Then NaBH₄ (18 mg, 0.42 mmol) was added. The diastereomeric amines 22c and 22d were separated by fc.

Compound 22c (R_f 0.77): Colourless oil, yield 68.7 mg (47%). IR (neat): ν/cm⁻¹ = 1692 (s, Cbz C [double bond, length as m-dash] O), 1205 (s)/1090 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.18–1.21 (m, 1H, 3-H), 1.42 (d broad, J = 13.4 Hz, 1H, 5-H), 1.53–1.64 (m, 1H, 5-H), 1.68 (d broad, J = 13.7 Hz, 1H, 3-H), 1.95 (d broad, J = 14.2 Hz, 1H, 6-H), 2.34 (s, 3H, NCH₃), 2.72 (quint, J = 4.0 Hz, 1H, 4-H), 3.20 (t broad, J = 12.7 Hz, 1H, 6-H), 3.70 (s broad, 1H, NH), 3.81–3.89 (m, 2H, OCH₂), 3.96–4.02 (m, 1H, 2-H), 4.81 (dt, J = 9.5/5.9 Hz, 1H, OCH), 4.99 (d, J = 12.7 Hz, 1H, OCH₂Ph), 5.04 (d, J = 12.7 Hz, 1H, OCH₂Ph), 7.13–7.28 (m, 11H, Ph), 7.37–7.43 (m, 4H, Ph). HRMS: calculated for C₂₉H₃₂N₂O₄H 473.2435, found 473.2420. HPLC (Method A): Purity 96%, t_R = 20.2 min.

Compound 22d (R_f 0.55): Colourless oil, yield 52.9 mg (36%). IR (neat): ν/cm⁻¹ = 1693 (s, Cbz C [double bond, length as m-dash] O), 1206 (s)/1070 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.28–1.38 (m broad, 1H, 3-H), 1.43–1.52 (m broad, 1H, 5-H), 1.94–2.02 (m broad, 1H, 3-H), 2.11–2.23 (m broad, 1H, 5-H), 2.35 (s, 3H, NCH₃), 2.78–3.09 (m broad, 2H, 6-H + 4-H), 3.87–4.02 (m broad, 2H, 6-H + NH), 4.16–4.39 (m, 3H, 2-H + OCH + OCH₂), 4.49 (t broad, J = 6.0 Hz, 1H, OCH₂), 5.05–5.11 (m, 2H, OCH₂Ph), 7.26–7.36 (m, 11H, Ph), 7.45–7.49 (m, 4H, Ph). HRMS: calculated for C₂₉H₃₂N₂O₄H 473.2435, found 473.2425. HPLC (Method A): Purity 94%, t_R = 20.3 min.

(±)-(2RS,4SR)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-N-methylpiperidin-4-amine (23a). According to General Procedure F 22a (94.5 mg, 0.20 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 9.0 mg) was added. The product was purified by fc. Compound 23a (R_f 0.29): Colourless oil, yield 60.2 mg (89%). IR (neat): ν/cm⁻¹ = 1068 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 0.85 (q, J = 11.5 Hz, 1H, 3-H_ax), 1.12 (qd, J = 12.3/4.2 Hz, 1H, 5-H_ax), 1.60 (dquint, J = 11.8/2.1 Hz, 1H, 5-H), 1.79–1.87 (m, 3H, 3-H + 2NH), 2.32 (tt, J = 11.7/4.1 Hz, 1H, 4-H), 2.33 (s, 3H, NCH₃), 2.49–2.59 (m, 2H, 6-H), 3.06 (ddd, J = 11.9/4.1/2.4 Hz, 1H, 2-H), 3.76–3.84 (m, 1H, OCH₂), 3.89–3.99 (m, 2H, OCH + OCH₂), 7.16–7.27 (m, 6H, Ph), 7.38–7.45 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 32.9 (C-5), 33.2 (C-3), 35.2 (NCH₃), 44.8 (C-6), 56.8 (C-2), 58.6 (C-4), 67.2 (OCH₂), 80.2 (OCH), 109.8 (OCO), 126.1 (Ph-C), 126.3 (Ph-C), 126.5 (Ph-C), 128.0 (Ph-C), 128.1(Ph-C), 128.2 (Ph-C), 142.0 (Ph-C), 142.2 (Ph-C). HRMS: calculated for C₂₁H₂₆N₂O₂H 339.2067, found 339.2071. HPLC (Method A): Purity 97%, t_R = 13.9 min.

(±)-(2RS,4RS)-2-[(4SR)-2,2-Diphenyl-1,3-dioxolan-4-yl]-N-methylpiperidin-4-amine (23b). According to General Procedure F 22a (37.6 mg, 0.08 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 4.0 mg) was added. The product was purified by fc. Compound 23b (R_f 0.32): Colourless oil, yield 21.2 mg (78%). IR (neat): ν/cm⁻¹ = 1067 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.29–1.36 (m, 1H, 3-H), 1.41 (d quint, J = 13.7/2.6 Hz, 1H, 5-H), 1.52–1.56 (m, 1H, 3-H), 1.61–1.69 (m, 1H, 5-H), 1.95 (s broad, 2H, 2NH), 2.31 (s, 3H, NCH₃), 2.73–2.81 (m, 2H, 6-H + 4-H), 2.84–2.93 (m, 2H, 6-H + 2-H), 3.72–3.77 (m, 1H, OCH₂), 3.93–3.97 (m, 2H, OCH + OCH₂), 7.19–7.27 (m, 6H, Ph), 7.36–7.45 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 30.3 (C-5), 32.8 (C-3), 34.1 (NCH₃), 40.4 (C-6), 52.6 (C-2), 54.2 (C-4), 67.6 (OCH₂), 79.7 (OCH), 110.1 (OCO), 126.4 (Ph-C), 126.5 (Ph-C), 126.6 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 142.2 (Ph-C), 142.3 (Ph-C). HRMS: calculated for C₂₁H₂₆N₂O₂H 339.2067, found 339.2061. HPLC (Method A): Purity 92%, t_R = 14.2 min.

(±)-(2RS,4SR)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-N-methylpiperidin-4-amine (23c). According to General Procedure F 22c (68.7 mg, 0.14 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 7.0 mg) was added. The product was purified by fc. Compound 23c (R_f 0.21): Colourless oil, yield 41.2 mg (87%). IR (neat): ν/cm⁻¹ = 1066 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 0.76 (q, J = 11.6 Hz, 1H, 3-H_ax), 1.08 (qd, J = 12.3/4.2 Hz, 1H, 5-H_ax), 1.54 (s broad, 2H, 2NH), 1.82 (ddd, J = 12.4/3.7/2.0 Hz, 1H, 3-H), 1.92 (dquint, J = 12.1/1.9 Hz, 1H, 5-H), 2.35 (tt, J = 11.1/3.9 Hz, 1H, 4-H), 2.34 (s, 3H, NCH₃), 2.54 (td, J = 12.3/2.5 Hz, 1H, 6-H), 2.80 (ddd, J = 11.6/4.3/2.3 Hz, 1H, 2-H), 3.04 (ddd, J = 12.1/4.0/2.6 Hz, 1H, 6-H), 3.87 (t, J = 7.2 Hz, 1H, OCH₂), 3.98 (td, J = 6.6/4.5 Hz, 1H, OCH), 4.08 (t, J = 7.2 Hz, 1H, OCH₂), 7.19–7.28 (m, 6H, Ph), 7.39–7.47 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 24.0 (C-5), 31.7 (C-3), 31.8 (NCH₃), 44.7 (C-6), 56.6 (C-2), 56.8 (C-4), 66.0 (OCH₂), 79.1 (OCH), 109.6 (OCO), 126.1 (Ph-C), 126.2 (Ph-C), 128.0 (Ph-C), 128.1 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 141.9 (Ph-C), 142.0 (Ph-C). HRMS: calculated for C₂₁H₂₆N₂O₂H 339.2067, found 339.2074. HPLC (Method B): Purity 99%, t_R = 11.3 min.

(±)-(2RS,4RS)-2-[(4RS)-2,2-Diphenyl-1,3-dioxolan-4-yl]-N-methylpiperidin-4-amine (23d). According to General Procedure F 22d (52.9 mg, 0.11 mmol) was dissolved in methanol (5 mL) and Pd/C (10%, 5.0 mg) was added. The product was purified by fc. Compound 23d (R_f 0.27): Colourless oil, yield 30.2 mg (82%). IR (neat): ν/cm⁻¹ = 1086 (s, C–O–C). ¹H NMR (CDCl₃): δ (ppm) = 1.44 (ddd, J = 12.2/10.1/3.6 Hz, 1H, 3-H), 1.54–1.59 (m, 2H, 5-H + NH), 1.62–1.67 (m, 2H, 3-H + NH), 1.69–1.74 (m, 1H, 5-H), 2.41 (s, 3H, NCH₃), 2.78 (dt, J = 12.4/4.1 Hz, 1H, 6-H), 2.88 (quint, J = 3.8 Hz, 1H, 4-H), 2.93 (td, J = 11.9/3.2 Hz, 1H, 6-H), 3.15 (ddd, J = 10.6/4.8/2.7 Hz, 1H, 2-H), 3.97 (t, J = 6.3 Hz, 1H, OCH₂), 4.02–4.10 (m, 2H, OCH + OCH₂), 7.27–7.36 (m, 6H, Ph), 7.46–7.54 (m, 4H, Ph). ¹³C NMR (CDCl₃): δ (ppm) = 31.0 (C-5), 32.8 (C-3), 34.2 (NCH₃), 41.0 (C-6), 52.5 (C-2), 52.8 (C-4), 66.7 (OCH₂), 79.4 (OCH), 109.8 (OCO), 126.4 (Ph-C), 126.5 (Ph-C), 128.1 (Ph-C), 128.2 (Ph-C), 128.3 (Ph-C), 128.4 (Ph-C), 142.4 (Ph-C), 142.5 (Ph-C). HRMS: calculated for C₂₁H₂₆N₂O₂H 339.2067, found 339.2067. HPLC (Method A): Purity 95%, t_R = 14.3 min.

Receptor binding studies

Materials and general procedures

Pig brains were a donation of the local slaughterhouse (Coesfeld, Germany). The guinea pig brains and rat livers were commercially available (Harlan-Winkelmann, Borchen, Germany). Homogenizer: Elvehjem Potter (B. Braun Biotech International, Melsungen, Germany). Centrifuge: high-speed cooling centrifuge model Sorvall RC-5C plus (Thermo Fisher Scientific, Langenselbold, Germany). Filter: printed Filtermat Typ A and B (Perkin Elmer LAS, Rodgau-Jügesheim, Germany), presoaked in 0.5% aqueous polyethylenimine for 2 h at room temperature before use. The filtration was carried out with a MicroBeta FilterMate-96 Harvester (Perkin Elmer). The scintillation analysis was performed using Meltilex (Typ A or B) solid scintillator (Perkin Elmer) and a MicroBeta Trilux scintillation analyzer (Perkin Elmer). The overall counting efficiency was 20%. All experiments were carried out in triplicates using standard 96-well-multiplates (Diagonal, Muenster, Germany). The IC₅₀-values were determined in competition experiments with at least six concentrations of the test compounds and were calculated with the program GraphPad Prism^® 3.0 (GraphPad Software, San Diego, CA, USA) by non-linear regression analysis. The K_i-values were calculated according to the formula of Cheng and Prusoff.²⁸ The K_i-values are given as mean value ± SEM from three independent experiments.

Affinity towards the phencyclidine binding site of the NMDA receptor, modified according to ref. 21

Preparation of the tissue. Fresh pig brain cortex was homogenized with the potter (500–800 rpm, 10 up-and-down strokes) in 6 volumes of cold 0.32 M sucrose. The suspension was centrifuged at 1200 × g for 10 min at 4 °C. The supernatant was separated and centrifuged at 23 [thin space (1/6-em)]

500 × g for 20 min at 4 °C. The pellet was resuspended in 5–6 volumes of TRIS/EDTA buffer (5 mM/1 mM, pH 7.5) and centrifuged again at 31 [thin space (1/6-em)]

000 × g (20 min, 4 °C). This procedure was repeated twice. The final pellet was resuspended in 5–6 volumes of buffer, the protein concentration was determined according to the method of Bradford³⁰ using bovine serum albumin as standard, and subsequently the preparation was frozen (−80 °C) in 1.5 mL portions containing about 0.8 mg protein mL⁻¹.

Performance of the assay. The test was performed with the radioligand [³H]-(+)-MK-801 (22.0 Ci/mmol; Perkin Elmer). The thawed membrane preparation (about 100 μg of the protein) was incubated with various concentrations of test compounds, 2 nM [³H]-(+)-MK-801, and TRIS/EDTA-buffer (5 mM/1 mM, pH 7.5) in a total volume of 200 μL for 150 min at rt. The incubation was terminated by rapid filtration through the presoaked filtermats using a cell harvester. After washing each well five times with 300 μL of water, the filtermats were dried at 95 °C. Subsequently, the solid scintillator was placed on the filtermat and melted at 95 °C. After 5 min, the solid scintillator was allowed to solidify at rt. The bound radioactivity trapped on the filters was counted in the scintillation analyzer. The non-specific binding was determined with 10 μM unlabeled (+)-MK-801. The K_d-value of (+)-MK-801 is 2.26 nM.²⁹

Affinity toards the σ₁ receptor, modified according to ref. 25–27

Preparation of the tissue. Five guinea pig brains were homogenized with the potter (500–800 rpm, 10 up-and-down strokes) in 6 volumes of cold 0.32 M sucrose. The suspension was centrifuged at 1200 g for 10 min at 4 °C. The supernatant was separated and centrifuged at 23 [thin space (1/6-em)]

500 g for 20 min at 4 °C. The pellet was resuspended in 5–6 volumes of buffer (50 mM Tris, pH 7.4) and centrifuged again at 23 [thin space (1/6-em)]

500 g (20 min, 4 °C). This procedure was repeated twice. The final pellet was resuspended in 5–6 volumes of buffer, the protein concentration was determined according to the method of Bradford³⁰ using bovine serum albumin as standard, and subsequently the preparation was frozen (−80 °C) in 1.5 mL portions containing about 1.5 mg protein mL⁻¹.

Performing of the σ₁ assay. The test was performed with the radioligand [³H]-(+)-pentazocine (42.5 Ci/mmol; Perkin Elmer). The thawed membrane preparation (about 75 μg of the protein) was incubated with various concentrations of test compounds, 2 nM [³H]-(+)-pentazocine, and buffer (50 mM TRIS, pH 7.4) in a total volume of 200 μL for 180 min at 37 °C. The incubation was terminated by rapid filtration through the presoaked filtermats by using the cell harvester. After washing each well five times with 300 μL of water, the filtermats were dried at 95 °C. Subsequently, the solid scintillator was placed on the filtermat and melted at 95 °C. After 5 min, the solid scintillator was allowed to solidify at rt. The bound radioactivity trapped on the filters was counted in the scintillation analyzer. The non-specific binding was determined with 10 μM unlabeled (+)-pentazocine. The K_d-value of the radioligand [³H]-(+)-pentazocine is 2.9 nM.

Affinity toards the σ₂ receptor (modified according to ref. 25–27)

Preparation of the tissue. Two rat livers were cut into small pieces and homogenized with a potter (500–800 rpm, 10 up-and-down strokes) in 6 volumes of cold 0.32 M sucrose. The suspension was centrifuged at 1200 g for 10 min at 4 °C. The supernatant was separated and centrifuged at 31 [thin space (1/6-em)]

000 g for 20 min at 4 °C. The pellet was resuspended in buffer (50 mM Tris, pH 8.0) and incubated at room temperature for 30 min. After the incubation, the suspension was centrifuged again at 31 [thin space (1/6-em)]

000 g for 20 min at 4 °C. The final pellet was resuspended in buffer, the protein concentration was determined according to the method of Bradford³⁰ using bovine serum albumin as standard, and subsequently the preparation was frozen (−80 °C) in 1.5 mL portions containing about 2 mg protein mL⁻¹.

Performing of the σ₂ assay. The test was performed with the radioligand [³H]-di-o-tolylguanidine (50 Ci/mmol; ARC). The thawed membrane preparation (about 100 μg of the protein) was incubated with various concentrations of test compounds, 3 nM [³H]-di-o-tolylguanidine, 500 nM (+)–pentazocine and buffer (50 mM TRIS, pH 8.0) in a total volume of 200 μL for 180 min at rt. The incubation was terminated by rapid filtration through the presoaked filtermats using a cell harvester. After washing each well five times with 300 μL of water, the filtermats were dried at 95 °C. Subsequently, the solid scintillator was placed on the filtermat and melted at 95 °C. After 5 min, the solid scintillator was allowed to solidify at rt. The bound radioactivity trapped on the filters was counted in the scintillation analyzer. The non-specific binding was determined with 10 μM unlabeled ditolylguanidine. The K_d-value of the radioligand [³H]-ditolylguanidine is 17.9 nM.

Affinity towards the ifenprodil binding site of the NMDA receptor (NR2B affinity), modified according to ref. 22

Cell Culture and harvesting of the cells. In the assay mouse L(tk−) cells stably transfected with the dexamethasone inducible eukaryotic expression vectors pMSG NR1a, pMSG NR2B in a 1 [thin space (1/6-em)]

5 ratio were used. The transformed L(tk−) cells were grown in Modified Earl's Medium (MEM) containing 10% of standardized FCS (Biochrom AG, Berlin, Germany). The expression of the NMDA receptor at the cell surface was induced after the cell density of the adherent growing cells had reached approximately 90% of confluency. For the induction, the original growth medium was replaced by growth medium containing 4 μM dexamethasone and 4 μM ketamine (final concentration). After 24 h the cells were harvested by scraping and pelleted (10 min, 5000 × g, Hettich Rotina 35R centrifuge, Tuttlingen, Germany).

Preparation of the cell membranes. For the binding assay, the cell pellet was resuspended in phosphate buffer saline (PBS) buffer and the number of cells was determined using an improved Neubauer's counting chamber (VWR, Darmstadt, Germany). Subsequently, the cells were lysed by sonication (4 °C, 6 × 10 s cycles with breaks of 10 s, device: Soniprep 150, MSE, London, UK). The resulting cell fragments were centrifuged with a high performance cool centrifuge (20 [thin space (1/6-em)]

000 × g, 4 °C, Sorvall RC-5 plus, Thermo Scientific). The supernatant was discarded and the pellet resuspended in a defined volume of PBS yielding cell fragments of approximately 500 [thin space (1/6-em)]

000 cells mL⁻¹. The suspension of membrane homogenates was sonicated again (4 °C, 2 × 10 s cycles with a break of 10 min) and stored at −80 °C.

Performing of the NR2B binding assay. The competitive binding assay was performed with the radioligand [³H]-ifenprodil (60 Ci/mmol; Perkin Elmer) using standard 96-well-multiplates (Diagonal, Muenster, Germany). The thawed cell membrane preparation (about 20 μg protein) was incubated with 6 different concentrations of test compounds, 5 nM [³H]–ifenprodil, and TRIS/EDTA-buffer (5 mM/1 mM, pH 7.5) in a total volume of 200 μL for 120 min at 37 °C. The incubation was terminated by rapid filtration through the presoaked filtermats by using the cell harvester. After washing each well five times with 300 μL of water, the filtermats were dried at 95 °C. Subsequently, the solid scintillator was placed on the filtermat and melted at 95 °C. After 5 min, the solid scintillator was allowed to solidify at rt. The bound radioactivity trapped on the filters was counted in the scintillation analyzer. The non-specific binding was determined with 10 μM unlabeled 1. The K_d-value of 1 is 7.6 nM.²²

Acknowledgements

The NRW International Graduate School of Chemistry, Münster, which is funded by the Government of the State Nordrhein-Westfalen and the DAAD is deeply acknowledged for the financial support.

References

H. Bräuner-Osborne, J. Egebjerg, E. O. Nielsen, U. Madsen and P. Krogsgaard-Larsen, J. Med. Chem., 2000, 43, 2609–2645 CrossRef .
W. P. Danysz, C. G. Bresink, I. Quack and G., Drug News Persp., 1995, 261–277 Search PubMed .
D. Lodge, in Excitatory Amino Acid Receptors- Design of Agonists and Antagonists, ed. P. Krogsgaard-Larsen, J. J. Hansen, Ellis Harwood Ltd., Chichester, 1992, pp 201–215 Search PubMed.
S. A. Lipton, Nat. Rev. Drug Discovery, 2006, 5, 160–170 CrossRef CAS .
W. R. Hardie, J. Hidalgo, I. F. Halverstadt and R. E. Allen, J. Med. Chem., 1966, 9, 127–136 CrossRef CAS .
A. E. Jacobson, E. A. Harrison, Jr., M. V. Mattson, M. F. Rafferty, K. C. Rice, J. H. Woods, G. Winger, R. E. Solomon, R. A. Lessor and J. V. Silverton, J. Pharmacol. Exp. Ther., 1987, 243, 110–117 CAS .
A. Thurkauf, M. V. Mattson, S. Richardson, S. Mirsadeghi, P. L. Ornstein, E. A. Harrison, Jr., K. C. Rice, A. E. Jacobson and J. A. Monn, J. Med. Chem., 1992, 35, 1323–1329 CrossRef CAS .
M. Aepkers and B. Wünsch, Bioorg. Med. Chem., 2005, 13, 6836–6849 CrossRef CAS .
M. Sax and B. Wünsch, Curr. Top. Med. Chem., 2006, 6, 723–732 CrossRef CAS .
M. Sax, K. Ebert, D. Schepmann, B. Wibbeling and B. Wünsch, Bioorg. Med. Chem., 2006, 14, 5955–5962 CrossRef CAS .
M. Sax, R. Fröhlich, D. Schepmann and B. Wünsch, Eur. J. Org. Chem., 2008, 6015–6028 CrossRef CAS .
G. A. Patani and E. J. LaVoie, Chem. Rev., 1996, 96, 3147–3176 CrossRef CAS .
A. J. Mancuso and D. Swern, Synthesis, 1981, 165–185 CrossRef CAS .
S. Danishefsky, Acc. Chem. Res., 1981, 14, 400–406 CrossRef CAS .
L. Hansson and R. Carlson, Acta Chem. Scand., 1989, 43, 188–192 CrossRef CAS .
P. Buonora, J. C. Olsen and T. Oh, Tetrahedron, 2001, 57, 6099–6138 CrossRef CAS .
S. K. Malhotra and F. Johnson, J. Am. Chem. Soc., 1965, 87, 5493–5495 CrossRef CAS .
E. E. Sugg, J. F. Griffin and P. S. Portoghese, J. Org. Chem., 1985, 50, 5032–5037 CrossRef CAS .
A. F. Abdel-Magid and S. J. Mehrman, Org. Process Res. Dev., 2006, 10, 971–1031 Search PubMed .
R. M. McKernan, S. Castro, J. A. Poat and E. H. F. Wong, J. Neurochem., 1989, 52, 777–785 CrossRef CAS .
U. Wirt, D. Schepmann and B. Wünsch, Eur. J. Org. Chem., 2007, 462–475 CrossRef CAS .
D. Schepmann, B. Frehland, K. Lehmkuhl, B. Tewes and B. Wünsch, J. Pharm. Biomed. Anal., 2010 DOI:10.1016/JPBA-D-09-01731R3 .
F. I. Carroll, P. Abraham, K. Parham, X. Bai, X. Zhang, G. A. Brine, S. W. Mascarella, B. R. Martin, E. L. May, C. Sauss, L. Di Paolo, P. Wallace, J. M. Walker and W. D. Bowen, J. Med. Chem., 1992, 35, 2812–2818 CrossRef CAS .
E. L. May, M. D. Aceto, E. R. Bowman, C. Bentley, B. R. Martin, L. S. Harris, F. Medzihradsky, M. V. Mattson and A. E. Jacobson, J. Med. Chem., 1994, 37, 3408–3418 CrossRef CAS .
C. A. Maier and B. Wünsch, J. Med. Chem., 2002, 45, 438–448 CrossRef CAS .
C. A. Maier and B. Wünsch, J. Med. Chem., 2002, 45, 4923–4930 CrossRef CAS .
R. Holl, D. Schepmann, R. Fröhlich, R. Grünert, P. J. Bednarski and B. Wünsch, J. Med. Chem., 2009, 52, 2126–2137 CrossRef CAS .
Y.-C. Cheng and W. H. Prusoff, Biochem. Pharmacol., 1973, 22, 3099–3108 CrossRef CAS .
Y. Ueda, H. Nakanishi and K. Yoshida, Life Sci., 1999, 65, 1477–1484 CrossRef CAS .
M. M. Bradford, Anal. Biochem., 1976, 72, 248–254 CrossRef CAS .

Footnote

† Electronic supplementary information (ESI) available: HPLC data. See DOI: 10.1039/c0md00017e

Click here to see how this site uses Cookies. View our privacy policy here.

Synthesis and NMDA receptor affinity of COMPOUND LINKSRead more about this on ChemSpiderDownload mol file of compounddexoxadrol analogues with modifications in position 4 of the COMPOUND LINKSRead more about this on ChemSpiderDownload mol file of compoundpiperidine ring†

Abstract

Introduction

Chemistry

Receptor binding studies

Conclusion

Experimental

Chemistry general

General procedures

Receptor binding studies

Materials and general procedures

Affinity towards the phencyclidine binding site of the NMDA receptor, modified according to ref. 21

Affinity toards the σ1 receptor, modified according to ref. 25–27

Affinity toards the σ2 receptor (modified according to ref. 25–27)

Affinity towards the ifenprodil binding site of the NMDA receptor (NR2B affinity), modified according to ref. 22

Acknowledgements

References

Footnote

Synthesis and NMDA receptor affinity of dexoxadrol analogues with modifications in position 4 of the piperidine ring†

Affinity toards the σ₁ receptor, modified according to ref. 25–27

Affinity toards the σ₂ receptor (modified according to ref. 25–27)